

PASPCR



March 2004
Vol. 12 Number 1

Newsletter

Introduction...

by **Bill Oetting**

NOTICE - Wanted - Read and Alive

The Bibliography listed in each Issue of the PASPCR Newsletter will be phased out at the end of 2004 - **UNLESS** - we can enlist the help of someone to take over. If you have a subscription to Current Contents (or any other literature awareness service), you could do this in just 1-2 hr every 3 months. The current PASPCR Bibliographer, after 10 years, has decided that other more pressing issues, such as organizing the IPCC in 2005, will consume too much of his time, and this literature search will end unless a volunteer steps forth to take it over. We would be happy to provide you with the searching keywords and algorithms used to generate the different categories of references listed in the PASPCR Bibliography. Want the adulation of your peers for years to come? Contact Bill Oetting or Vince Hearing.


The *PASPCR Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. You are invited to contribute articles, or other information you feel will be of interest to members of the **PASPCR**. If you attend a scientific meeting and have heard results which you think will be of interest to the membership of the PASPCR, please write a few paragraphs summarizing what was presented and share it with us. Any information on upcoming meetings of interest will be added to the "Calendar of Events". This is your newsletter, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to me, preferably by E-mail, to bill@lenti.med.umn.edu.

The PASPCR Web Site is the major, up-to-date source of current information for the PASPCR membership and for individuals who are interested in the PASPCR. If there is additional information that you would like to see on the Web site, or you

would like to include information of past PASPCR activities, please let me know and I will add them.

New Internet Addresses

The web server for the PASPCR and IFPCS websites is in the process of being changed. The internet address for the PASPCR website will now be paspcr.med.umn.edu and the address for the IFPCS web site is now ifpcs.med.umn.edu. Of course, **paspcr.org** and **ifpcs.org** will take you directly to the home page for each. The domain name **ipcc.info** will take you to the IPCC web site, providing you the most up to date information on the International Pigment Cell Conference which will be held on September 18 - 22, 2005 at the Hyatt Regency Hotel in Reston, VA.

 Don't forget to register for the XIIth Annual Meeting of the PASPCR, to be held in Irvine, California. You will need to register both for the meeting and your hotel room. Go to the registration page of the PASPCR for more information.

In this Issue

PASPCR Officers.....	2
Calendar of Events.....	2
Corporate Sponsors.....	3
PASPCR Election Results.....	3
PASPCR on the 'Net' for 10 Years.....	3
The Coat Colors of Mice.....	3
Lynn's Column.....	4
Pigment Cell Development Group.....	5
Research in the PASPCR.....	6
Letter from the PCR Editor.....	7
PASPCR XII th Annual Meeting Program....	8
Job Positions.....	14
Bibliography.....	15
Member Contact Information.....	35

The PanAmerican Society for Pigment Cell Research

C/O Dr. Raymond E. Boissy
Department of Dermatology
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0592

Officers:

Zalfa Abdel-Malek,
President
John Pawelek
President-elect
Raymond E. Boissy
Secretary/Treasurer

Council Members:

Gregory Barsh
Murray Brilliant
Gisella Erf
Bryan Fuller
Ruth Halaban
Seth Orlow
Brian Potterf
Manickam Sugumaran
Richard Swank

IFPCS Representative:

Richard A. King
past-President PASPCR

Calendar of Events:

- June 24-27, 2004** XIIth Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Irvine, California.
Contact: Frank Myskins.
E-mail: flmeyske@uci.edu
Web: www.paspcr.org
- July 22-24, 2004** International Skin Cancer Conference, Zurich, CH
President: Günter Burg
Contact: Reinhard Dummer
Phone: +41 1 255 88 37
Fax: +41 1 255 44 03
E-mail: nicole.brunner@usz.ch
Web: www.skincancer.ch
- Sept 22-25, 2004** XIIth Meeting of the European Society for Pigment Cell Research, to be held in Paris, France.
Contact: Dr. Lionel LaRue
E-mail: Lionel.Larue@curie.fr
Web: http://espcr2004.curie.fr/
- Nov 27-28, 2004** The 18th Annual Meeting of the Japanese Society for Pigment Cell Research, to be held in Kumamoto City, Japan.
Contact: Dr. Toshiro Kageshita
E-mail: toshiro@kaiju.medic.kumamoto-u.ac.jp
- Sept 18-22, 2005** XIVth International Pigment Cell Conference (IPCC), to be held near Washington DC, USA.
Contact: Dr. Vince. Hearing
E-mail: hearingv@nih.gov
Web: www.ipcc.info

If you know of future meetings that you feel would be of interest to the PASPCR membership, please let us know.

The *PASPCR Newsletter* is published quarterly by the PanAmerican Society for Pigment Cell Research. All views are those of the authors. For further information or to submit articles, please contact members of the Publications Committee.

Publications Committee:

William S. Oetting, Ph.D. Editor

University of Minnesota
Department of Medicine- Genetics
MMC 485
420 Delaware St. SE
Minneapolis, MN 55455
(612) 624-1139
bill@lenti.med.umn.edu

Manickam Sugumaran, PhD

Univ of Massachusetts at Boston
Department of Biology
100 Marrissey Boulevard
Boston, MA 02125
(617) 287-6600
manickam.sugumaran@umb.edu

Richard T. Swank, PhD

Roswell Park Cancer Institute
Department of Molecular & Cell Biology
Elm and Carlton Streets
Buffalo, NY 14263
(716) 845-3429
richard.swank@roswellpark.edu

Corporate Sponsors *by Raymond E. Boissy*

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons
Procter and Gamble Co.
Shiseido Co, Ltd.
Combe, Inc.

SILVER Corporate Patrons
Avon Products, Inc.
Galderma Laboratories, Inc
Stiefel Laboratories

PASPCR Election Results *by Raymond E. Boissy*

Congratulations to the new members of the PASPCR council. Or new council members for the 2004-2006 term are:

Gregory Barsh
Murray Brilliant and
Seth Orlow

We would like to thank:

Thomas J. Hornyak
Glynis Scott and
Miri Seiberg

for their service from 2001 to 2003.

Thank you!!!

PASPCR on the 'net' for 10 Years *by Bill Oetting*

The PASPCR has had an internet presence for over 10 years. The PASPCR was officially put on-line as a Gopher site on February 28th, 1994 by DeWayne Townsend. This site contained information both for the PASPCR and the IFPCS, which included the first copy of the InterPig Database. The first Web page was available in 1995, initially created by Vince Hearing and later moved that year to a University of Minnesota web server, where it has remained. As stated in the last issue of the PASPCR Newsletter, the PASPCR web site has been receiving visits from all over the world. Over 40% of our visits come from outside the United States. This is a powerful (and inexpensive) way to get our information about our society to other individuals interested in pigment biology.

Please check out the PASPCR web site at paspcr.org. Forward any suggestions to me and I will try to incorporate them into the website. This site belongs to the PASPCR membership, and your input is necessary to make sure that this information reflects the PASPCR community.

The 'Coat Colors of Mice' **the electronic version** *by Bill Oetting*

The Coat Colors of Mice, A Model for Mammalian Gene Action and Interaction, by Willys K. Silvers, originally published by Springer Verlag in 1979, has been Adapted for the Web by the Mouse Genome Informatics (MGI) group at The Jackson Laboratory, Bar Harbor, Maine. The web address is www.informatics.jax.org/wksilvers/. This website contains text from the book, including hyperlinks for references, pictures of mutant mice and pages from the Jackson Laboratories Mouse genome Informatics database. The Principal Investigator for this project is Janan T. Eppig, Senior Staff Scientist at the Jackson Laboratory and text entry, graphics, and HTML adaptation is being done by Paul Szauter. The MGI group is asking for comments on this site, so check it out and let then know what you think.

Lynn's Column

by Lynn Lamoreux

How fine it is that we have been able to cryopreserve our CONGENIC MODEL, a set of mice for our use and the use of people who study our pleiotropic effects. These mice are now becoming available at WWW.MMRRC.org.

When you look at the Mouse Mutant Research Resources page you will not see our group of mice neatly organized as they are in the table provided here. It may be easier to find your mouse on the table and check its number. The number, for example number 136, indicates the MMRRC order number, which includes the 136. Or go to the MMRRC web site, under available strains, and look for the locus or genotype of interest. Our mouse number 137 is the second mouse on their list. IF, and only if, that particular stock is already cryopreserved and available, there is an asterisk next to the number on

the table included here. Otherwise, we are working on it.

Another resource is new. If you would like a CD with photographs of all (almost, soon) these mice, just contact Lynn Lamoreux at MLLamoreux@hotmail.com. At present, the CD gives you pictures in gif format, you must dig through them to find what you want, but at least all are pigment mutants. Eventually the disk will be searchable by key words, and connectable to the relevant web sites, ours, MMRRC, JAX and our cell bank that contains several cell lines that are congenic with the mice stored at MMRRC. But that will take a while. You might as well admire the photos now. They may be used but not copywrited.

REMEMBER, as they say at MMRRC. They didn't actually say use it or lose it. They said: "The best way to ensure the continuing maintenance of these stocks is to use them."

Locus

Inbred Strain
inbred strain, agouti, MyoVa, Tyrp1
Agouti, Endothelin Receptor B
Tyrosinase
Tyrosinase
Dopachrome tautomerase
silver
silver, Tyrosinase-related protein 1
ruby-eye 2
agouti, nonagouti
agouti, nonagouti
agouti, nonagouti, tyrosinase
extension, Melanocortin receptor 1
Attractin
Microphthalmia
PAX3
Kit
Endothelin Receptor B
Endothelin 3
Adamts2
Adamts2, Melanocortin receptor 1
Tyrosinase, Dopachrome tautomerase, Tyrosinase related protein 1
Kitl

Source (web address)

<http://www.mmrrc.org/strains/136/0136.html>
<http://www.mmrrc.org/strains/137/0137.html>
<http://www.mmrrc.org/strains/138/0138.html>
<http://www.mmrrc.org/strains/139/0139.html>
<http://www.mmrrc.org/strains/142/0142.html>
<http://www.mmrrc.org/strains/150/0150.html>



2004 Pigment Cell Development Workshop

**The Cloisters
National Institutes of Health
Bethesda, Md.
April 28-30, 2004**

Pigment Cell Development Group Workshop

Dear Friends and Colleagues:

As most of you know the Pigment Cell Development Interest Group has had three meetings to date. The first and third were one-day Satellite Meetings held in conjunction with the International Pigment Cell Society meetings held in Nagoya in 1999 and Amsterdam in 2002. The group expressed an interest in having focused workshops situated between the International Conferences. The first of these workshops was a three-day gathering in 2001 at the National Institutes of Health Campus.

We are pleased to announce that we have reserved the same facilities on the National Institutes of Health Campus in Bethesda Maryland, USA for a workshop to be held from April 28 to April 30th, 2004. A limited number of travel fellowships are available.

The website is now available for registration: **<http://www.genome.gov/11509839>**

There are several important deadlines to consider:

If you would like to apply for a travel fellowship, your registration and abstract must be completed

by February 14th so that we can notify you by February 29th if you will receive the funding.

For everyone including travel fellowship recipients, You must confirm you own hotel reservations by March 16th if you would like to take advantage of the conference rates. Information is on the website. After this date, we must give up the remaining rooms or we will have to pay for them.

Also, if you would like to be considered for an oral presentation of your abstract, please register by March 16th so we can plan the program.

Please feel free to contact anyone of us if you have any questions or suggestions.

Best wishes:

IFPCS DEVELOPMENTAL BIOLOGY GROUP.

Co-chairs:

Robert Kelsh, UK bssrnk@bath.ac.uk

Hiroaki Yamamoto, JAPAN

hyamamot@mail.cc.tohoku.ac.jp

Bill Pavan, USA bpavan@mail.nih.gov

For more information, go to the web site at:

Web Site: <http://www.genome.gov/11509839>.

Research in the PASPCR

In the last issue of the PASPCR newsletter, we began a new section that will highlight the major research focus of laboratories of PASPCR members. Our hope is that this information will be useful to all within the PASPCR by presenting the major research project in our laboratories and possibly opening doors for collaboration. In this issue, John Pawelek describes some of the projects in his laboratory.

John Pawelek is a Senior Research Scientist at the Yale University School of Medicine. His most recent research collaborators are David Bermudes, PhD, Ashok Chakraborty, PhD, Tamara Handerson, MD, Rossitza Lazova, MD, Brooks Low, PhD, James Platt, BS, Reena Rupani, medical student, and Stefano Sodi, BS. Dr. Pawelek's career has focused on mechanisms of melanoma pigmentation and metastatic progression. Achievements from his group include establishment of cell culture systems for studying the action of MSH (melanocortin); identification of MSH receptors; demonstration that MSH receptors are upregulated by UV light; demonstration that in addition to melanogenesis, MSH regulates melanoma cell motility and morphology; discovery of TYRP-2 (dopachrome tautomerase); and commercial development of Melasyn™, a class of water soluble, plant derived melanins for use in sun-protection and self-tanning. For the past 10 years, Dr. Pawelek has studied a long-proposed theory that melanoma metastasis is caused by hybridization between tumor-invading phagocytes and melanoma cells of the primary tumor. These studies have led to recent discoveries of common expression of macrophage-like glycosylation in human melanoma, and associations between this aberrant glycosylation, abnormal pigmentation, and tumor metastasis. The macrophage-like characteristics of human melanomas have led to development of new treatment therapies based on targeting tumors with bacterial vectors expressing macrophage recognition capabilities.

The PASPCR XIIth Annual Meeting



See you in sunny California

We are looking for:

items to include in the *PASPCR Newsletter*. Please send in information that you have on:

- Meetings of interest
- Reports on meetings you have attended
- News about PASPCR members
- Short stories
- Interesting graphics

or anything else you think that the PASPCR membership would be interested in reading. Please email your contributions to bill@lenti.med.umn.edu.

Thanks!



Letter from the PCR Editor

Dear Colleagues :

Time has a way of flying by and that has been quite true of my tenure as **Editor of *Pigment Cell Research***. The term of the Editor is 5 years, which seems like a long time at the beginning but in reality it goes by very quickly. I've been immensely pleased by the progress of the journal over that time span and I suppose all of you are aware of its expansion in terms of pages per volume, number of color figures, impact factor, and yes, even subscription fee. While we all would like to keep the price of the journal where it was for many years, the reality of inflation eventually takes a toll and after 6 years at a stagnant price, the publisher recently had to increase the price of the journal, even the discounted member cost, to keep pace with rising costs. The alternative (decreases in pages, color, etc.) is simply not worth thinking about. It has taken too much to build the journal to its current state to slip backwards.

The sum of our efforts to improve the journal have paid off in many ways. I think that the Reviews featured in each issue have been extremely valuable to our members and the wide citation of those in the literature has benefited us as well. Perhaps the most common feedback I have heard over the years has been about the quality and usefulness of those Reviews. It may be transparent to you, but the number of articles submitted has risen dramatically in recent years and is at an all time-high at the moment. This means less than 50% of manuscripts submitted can be accepted for publication, which makes some authors unhappy I know, but we simply have no choice about that and the increase in quality of manuscripts keeps the pressure on to improve the status of the journal. As a measure of growth, from 44 Articles submitted in 2000, those have increased each year and in 2003, 68 Articles were submitted (this year we have 68 submissions already and the publication year is only 50% completed). The rejection rate has also slowly increased from 35% in 2000 to a current rate of >50%. We have accommodated the increase in part because of the 25% increase in allotted pages in each issue, and in part because we now pay for about 20 extra pages in each issue, either from page charges assessed to authors for exceeding the standard limit of 7 journal pages per article, or from the Editor's budget. If you want to see more details about journal activities and statistics, please visit the Web Site at www.pigment.org and look at the PCR Statistics page. I have also recently updated the Top 50 Cited Articles in PCR and you can see there the rapidly rising articles that are being highly cited.

So what does the future hold for *Pigment Cell Research*? I think the picture is quite bright at this point. From many perspectives, the key measure of any journal is its Impact Factor and ours has been climbing steadily (for 6 straight years actually). The final number for 2003 won't be known for another month or two but if it was calculated today (early February) it would be a little above 2.50. That is quite an improvement from the days when we hovered around 1.00 and that number puts us solidly in the top half of the highly competitive Cell Biology category of Current Contents. Can we do better? Absolutely, and I think that is destined to happen as only the strongest of papers submitted will be published in *Pigment Cell Research* in the future.

Even better, the next Editor of the journal has been chosen by the IFPCS Council, and Prof. Colin Goding has taken on that challenge with enthusiasm. You will no doubt be hearing soon of his plans to take *Pigment Cell Research* to the next level, and I know that everyone will be united behind him to continue the growth and dynamics of our journal during his term. At this point, I have another 6 months or so before beginning to turn my duties over to his office and I still welcome feedback from all scientists in the field on how to improve the journal and make it more useful to all of us.

Congratulations to the two PCR Award winners for 2003. The Glynis Scott laboratory won the Outstanding Article Award for 2003 for their article entitled "The cAMP Signaling Pathway Has Opposing Effects on Rac and Rho in B16F10 Cells: Implications for Dendrite Formation in Melanocytic Cells" published in *Pigment Cell Research* 2003; 16: 139-148. **Dr. Mayuko Kumasaka** from the Yamamoto laboratory was selected as recipient of the Young Investigator Award for 2003; she was the first author of an article entitled "Isolation and Developmental Expression of Tyrosinase Family Genes in *Xenopus laevis*", published in *Pigment Cell Research* 2003; 16: 455-462. Details of those 2 awards will be published in Issue #2 and will be available soon on the web site.

Now what will I do with all my free time once my duties as Editor are completed? Well I imagine some of it will be taken up in organizing the 19th International Pigment Cell Conference to be held near NIH from September 18-22, 2005. We have an active functional web site (www.ipcc.info) that will gradually develop as the meeting matures; the outline of the scientific program and the meeting venue is already posted there. Please feel free to check it anytime to see what has been added and I'll look forward to welcoming you that meeting late next year. Let me wish continued success to all of you.

Vincent J. Hearing
PCR Editor

**PASPCR XIIth Annual Meeting
Implication of Pigment Cell Biology for
Understanding Human Diseases**

**The Sutton Place Hotel
Newport Beach, CA
June 24-27, 2004**

The annual meeting of the Pan American Society for Pigment Cell Research will be held this year at the Sutton Place Hotel in Newport Beach. The theme will be "Implications of Pigment Cell Biology for Understanding Human Disease: and will cover all the major areas of chemistry and molecular and cellular biology relevant to this topic. To enhance the meeting, eight major non-PASPCR members have been invited to provide invited lectures addressing specific areas of pigment cell biology. Two special lectures will be offered on the topics of polyamines (E. Gerner, University of Arizona) and mitochondria (D. Wallace, University of California, Irvine) and disease. A special organizer's session on melanin function will also be offered and will cover advances in the chemistry and biology of this compound. The Aaron B. Lerner lecture will be given by John Pawelek of Yale University. We look forward to seeing you in June.

Frank L. Meyskens Jr., M.D., F.A.C.P.
Professor of Medicine and Biological Chemistry
Director, Chao Family Comprehensive Cancer Center

Social Activities

Here is a description of the social activities planned for the XIIth Annual Meeting of the PASPCR.

Thursday, June 24, 2004:

There will be a reception immediately following our program at 5:00 p.m. where attendees will have the opportunity to meet our invited speakers.

Friday, June 25, 2004:

A Poster Session is scheduled with authors from 5:30 p.m. – 7:00 p.m. In addition, posters will be on display for the duration of the conference.

Saturday, June 26, 2004:

There will be a one hour Harbor Sunset Cruise Saturday evening.

All those who have signed-up for the cruise will be transported from The Sutton Place Hotel to Hornblower, for a cruise of the Newport Beach Harbor. Light refreshments will be served on board.

We will be cruising on the "Zumbrota," which is a beautiful yacht built in 1918 for Ringling Brothers, and has had a colorful list of owners, including Mae West and Douglas Fairbanks, Jr. At the end of the cruise, we will have transportation available to bring everyone back to the hotel.

The fee for the cruise is included in your registration for the conference. However, if you wish to bring a guest, there will be a fee of \$60. Sign-up for the cruise is on the registration form for the conference which will be mailed out early April, or you can access it on our website at <http://www.ucihs.uci.edu/cancer/events/carcinogenesisRegistration/registration.htm>. The yacht can accommodate 75 people. Therefore, the first 75 people who register for the cruise will be able to attend.

PRELIMINARY AGENDA: JUNE 24-27, 2004
The Sutton Place Hotel, Newport Beach, CA

Thursday, June 24, 2004

12:00 – 12:45 p.m. Registration and Poster Session

12:45 – 1:00 p.m. **Welcome and Program Overview**
Frank L. Meyskens, Jr., M.D.,** University of California, Irvine
Zalfa Abdel-Malek, Ph.D.,** President of PASPCR

SESSION I: The Genetics of Pigment Cell Diseases
Moderators: William S. Oetting, Ph.D., University of Minnesota
and TBA

1:00 – 1:20 p.m. ***The Epidemiology of Melanoma (Invited Lecture)***
Margaret A. Tucker, Ph.D.,* National Cancer Institute

1:20 – 1:30 p.m. Questions

1:30 – 2:15 p.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)

2:15 – 2:30 p.m. **Break**

2:30 – 2:50 p.m. ***BRAF and Melanocytic Diseases (Invited Lecture)***
Daniel Pinkel, Ph.D.,* University of California, San Francisco

2:50 – 3:00 p.m. Questions

3:00 – 4:00 p.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)

4:00 – 4:40 p.m. **State-of-the-Sciences Presentation**
Mitochondrial Role in Aging and Cancer
Douglas C. Wallace, Ph.D.,* University of California, Irvine

4:40 – 4:50 p.m. Questions

Reception Immediately following - Meet the Invited Speakers

Poster Session: Posters will be on display for observation during the conference. A designated time for poster review is also shown.

* Non-Members of PASPCR

** Members of PASPCR

+ Presidential Talks occur only in the last year of the president's tenure.
Dr. Abdel-Malek's is 2001-2004.

Friday, June 25, 2004

7:30 – 8:00 a.m. Registration and Continental Breakfast

Session II: Mechanisms of Melanocyte Proliferation and Differentiation
Moderators: Zalfa Abdel-Malek, Ph.D.,** University of Cincinnati and TBA

8:00 – 8:20 a.m. *Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas (Invited Lecture)*
Ruth Halaban, Ph.D.,** Yale University School of Medicine

8:20 – 8:30 a.m. Questions

8:30 – 8:50 a.m. *The Role of NF- κ B Disregulation in Melanoma Tumor Growth (Invited Lecture)*
Ann Richmond, Ph.D., VA Medical Center and Vanderbilt University

8:50 – 9:00 a.m. Questions

9:00 – 10:00 a.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)

10:00 – 10:15 a.m. **Break**

10:15 – 10:35 a.m. *Chromatin, Cell Cycle Control and Melanocyte Senescence (Invited Lecture)*
Estela Medrano, Ph.D.,** Baylor College of Medicine

10:35 – 10:45 a.m. Questions

10:45 – 11:30 a.m. **Aaron B. Lerner Lecture**
Melanoma Pigmentation and Progression: Some New Things Under the Sun
John M. Pawelek, Ph.D.,** Yale University School of Medicine

11:30 – 11:45 a.m. Questions

11:45 – 1:00 p.m. **Hosted Lunch** - Bistro Garden Restaurant in the hotel

Posters will be displayed for the duration of the conference

CONFERENCE ORGANIZER'S SESSION:

Session III: The Properties of Melanin and Melanosomes and its Potential for Understanding Pigment Cell Disease
Moderators: Patrick J. Farmer, Ph.D., ** University of California, Irvine and TBA

1:00 – 1:20 p.m. *Hermansky-Pudlak Syndrome: BLOCKing Melanosome Biogenesis (Invited Lecture)*
Esteban C. Dell'Angelica, Ph.D., ** University of California, Los Angeles

-
- 1:20 – 1:30 p.m. Questions
- 1:30 – 1:50 p.m. ***Structural Studies of Melanin (Invited Lecture)***
John D. Simon, Ph.D., * Duke University
- 1:50 – 2:00 p.m. Questions
- 2:00 – 2:20 p.m. ***Redox Properties of Melanin (Invited Lecture)***
Patrick J. Farmer, Ph.D., ** University of California, Irvine
- 2:20 – 2:30 p.m. Questions
- 2:30 – 2:50 p.m. ***Antioxidant Properties of Human Iridial Mela (Invited Lecture)***
Tad Sarna, Ph.D., * Jagiellonian University, Krakow, Poland
- 2:50 – 3:00 p.m. Questions
- 3:00 – 3:20 p.m. **Special Presentation**
***Biology of Clinical Chemoprevention of Human Melanoma:
Some New Thoughts***
Frank L. Meyskens, Jr., M.D., ** University of California, Irvine
- 3:20 – 3:30 p.m. Questions
- 3:30 – 3:45 p.m. **Break**
- 3:45 – 4:30 p.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)
- 4:30 – 4:50 p.m. **State-of-the-Sciences Presentation**
The Plasticity of Human Melanoma Cells
Mary Hendrix, Ph.D., * University of Iowa
- 4:50 – 5:00 p.m. Questions
- 5:00 – 5:20 p.m. **Special Presentation**
From PAR-2 and Melanosomes to Soy: Basic Research and Applications
Miri Seiberg, M.D., ** Johnson & Johnson
- 5:20 – 5:30 p.m. Questions
- Adjourn**
- 5:30 – 7:00 p.m. Poster Session with authors

Saturday, June 26, 2004

7:30 – 8:00 a.m. Registration and Continental Breakfast

SESSION IV: Newer Animal Models of Pigmentary Abnormalities and Melanoma
Moderators: Roger Bowers, Ph.D., Cal State, Los Angeles and TBA

8:00 – 8:45 a.m. **“Presidential Talk”**
Photobiological Responses of Human Melanocytes
Zalfa Abdel-Malek, Ph.D., ** +University of Cincinnati

8:45 – 8:55 a.m. Questions

8:55 – 9:15 a.m. ***The Zebrafish as a Genetics Model for the Study of Pigmentation (Invited Lecture)***
Steve Ekker, Ph.D., * University of Minnesota

9:15 – 9:25 a.m. Questions

9:25 – 9:45 a.m. ***UV Induction of Melanoma in HGF/SF Transgenic Mice (Invited Lecture)***
Frances P. Noonan, Ph.D., ** George Washington University

9:45 – 9:55 a.m. Questions

9:55 – 10:10 a.m. **Break**

10:10 – 11:25 a.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)

11:25 – 11:45 a.m. **Special Presentation**
Polyamines in Development, Tissue Repair and Cancer (Invited Lecture)
Eugene Gerner, Ph.D. * University of Arizona

11:45 – 11:55 Questions

11:55 – 1:00 p.m. **Hosted Lunch** – Bistro Garden Restaurant in hotel

SESSION V Non-Malignant Abnormalities of Pigment Cells
Moderators: William S. Oetting, Ph.D., University of Minnesota and TBA

1:00 – 1:20 p.m. ***Avian Neural Crest Cell Induction (Invited Lecture)***
Martin Garcia-Castro, Ph.D.* California Institute of Technology

1:20 – 1:30 p.m. Questions

1:30 – 1:50 p.m. ***The Genetics of Albinism and Pigment Variation (Invited Lecture)***
Murray H. Brilliant, Ph.D., ** Arizona Health Sciences Center

-
- 1:50 – 2:00 p.m. Questions
- 2:00 – 2:15 p.m. **Break**
- 2:15 – 4:15 p.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)
- 5:30 – 7:30 p.m. **Newport Harbor Sunset Cruise**

Sunday, June 27, 2004

- 8:30 – 9:00 a.m. Registration and Continental Breakfast

SESSION VI: Advances in Understanding the Biology of Melanoma and its Consequences
Moderators: Alistair Cochran, M.D.* , University of California, Los Angeles and TBA

- 9:00 – 9:20 a.m. ***Molecular Assessment of Melanoma Progression (Invited Lecture)***
David S. Hoon, MSc, PhD,* John Wayne Cancer Institute
- 9:20 – 9:30 a.m. Questions
- 9:30 – 9:50 a.m. ***Update on the Sentinel Node Procedure (Invited Lecture)***
Alistair Cochran, M.D.* University of California, Los Angeles
- 9:50 – 10:00 a.m. Questions
- 10:00 – 10:40 a.m. **Competitive Platform Presentations**
(10 minute presentations with 5 minutes for questions)

Positions - Wanted and Available

Postings for **Positions Available** will be open to all individuals and institutions so long as the position is related to pigment cell research. Postings for **Positions Wanted** will be open only to members of the PanAmerican Society for Pigment Cell Research or its sister societies (JSPCR and ESPCR). Send postings to Bill Oetting at bill@lenti.med.umn.edu. Please provide an expiration date for any submitted postings. Final decisions will be made by the Publications Committee of the PASPCR.

Postdoctoral Associate Position

A postdoctoral research position is available for work on the development of melanocytes and their malignant progression to cutaneous metastatic melanomas in this laboratory's melanoma-susceptible transgenic mouse model. The basis for newly recognized phenomena will be investigated in the areas of apoptosis, imprinting, hypoxia-inducible gene expression, and cell migration. Some of the results are expected to provide a basis for novel experimental treatments of mice with malignant melanoma. A recent Ph.D. or M.D./Ph.D. degree is required, with strong specialization in molecular and cell biology. Please send a C.V., summaries of publications, and names of three references to:

Dr. Beatrice Mintz
Fox Chase Cancer Center
7701 Burholme Avenue
Philadelphia, PA 19111 USA
FAX: (215) 728-3574
E-mail: beatrice.mintz@fccc.edu

Department of Dermatology Chair

The University of California, Irvine, College of Medicine seeks candidates for the position of Chair, Department of Dermatology. The candidate must be an accomplished investigator, clinician and teacher, eligible for appointment at the level of associate professor or professor, with leadership skills appropriate for a major university department. Send CV, plus names and addresses of at least three references to:

Frank L. Meyskens, Jr., M.D.
Chair, Dermatology Search Committee
c/o Kit Scott
UCI College of Medicine

Dean's Office
246 Irvine Hall
Irvine, CA 92697-3950

The University of California is an Equal Opportunity Employer committed to excellence through diversity.

Postdoctoral Position

A Postdoctoral Position is available to study the role of UV radiation in the development of primary melanoma. The project will use transgenic and pigment cell mutant mice and cell cultures to study molecular mechanisms of melanoma initiation and progression. A strong background in pigment cell biology, cellular mechanisms of toxicology, carcinogenesis, or molecular biology is desired. Send curriculum vitae, names of 3 references, and a brief summary of research interests to:

Faith M. Strickland, Ph.D.
Dermatology Research 4D49
Henry Ford Hospital
One Ford Place
Detroit, MI 48202
E-mail: FSTRICK1@hfhs.org
Phone: 313-874-3385
FAX: 313-874-3770.

An Equal Opportunity Employer. Smoke-free/drug free environment.

Postdoctoral Research Associate

Fox Chase Cancer Center.
Two NIH-funded postdoctoral positions are available to work on the development of neural crest-derived melanocytes and enteric neurons in mice. We are interested in the signals required for proper migration and differentiation of these lineages during mouse embryogenesis and use various genetic manipulation techniques and existing mutants for our studies. Fox Chase Cancer offers competitive salaries to its postdocs and was recently named one of the best places to work for Postdocs (<http://www.fccc.edu/news/2003/Best-Places-for-Postdocs-02-20-2003.html>). Candidates with a recent PhD or MD/PhD with strong background in molecular biology, genetics or developmental biology are encouraged to apply. Please submit CV, and names of 3 references to:

Dr. Myung K. Shin
Program in Cellular and Developmental Biology
Fox Chase Cancer Center
Philadelphia, PA 19111, USA
Email: MK_Shin@fccc.edu

Bibliography:

The Bibliography published in this issue covers the period December, 2003 through February 2004. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category is arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field.

MELANINS, MELANOGENS & MELANOGENESIS

- Ali FE, Barnham KJ, Barrow CJ, Separovic F: Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. *J INORG BIOCHEM* 98:173-184 (2004).
- Bókony V, Liker A, Székely T, Kis J: Melanin-based plumage coloration and flight displays in plovers and allies. *PROC ROY SOC LONDON SER B* 270:2491-2497 (2003).
- Butler M, Johnson AS: Are melanized feather barbs stronger? *J EXP BIOL* 207:285-293 (2004).
- Churukian CJ: Microwave methods for demonstrating melanin. *J HISTOTECHNOL* 26:239-243 (2003).
- Costin GE: What is the advantage of having melanin in parts of the central nervous system (e.g. substantia nigra)? *IUBMB LIFE* 56:47-49 (2004).
- Icenhour CR, Kottom TJ, Limper AH: Melanin-like pigments in *Pneumocystis carinii*. *J EUKARYOT MICROBIOL* 50:621 (2003).
- Jones ML: Histochemical stains for melanin: The classics. *J HISTOTECHNOL* 26:233-237 (2003).
- Kihara J, Moriwaki A, Ito M, Arase S, Honda Y: Expression of THR1, a 1,3,8-trihydroxynaphthalene reductase gene involved in melanin biosynthesis in the phytopathogenic fungus *Bipolaris oryzae*, is enhanced by near-ultraviolet radiation. *PIGM CELL RES* 17:15-23 (2004).
- Kim JP, Kim BY, Yun BS, Ryoo IJ, Lee IK, Kim WG, Pyun YR, Yoo ID: Melanocins A, B and C, new melanin synthesis inhibitors produced by *Eupenicillium shearii* - II. Physico-chemical properties and structure elucidation. *J ANTIBIOT* 56:1000-1003 (2003).
- Kim JP, Kim BK, Yun BS, Ryoo IJ, Lee CH, Lee IK, Kim WG, Lee SK, Pyun YR, Yoo ID: Melanocins A, B and C, new melanin synthesis inhibitors produced by *Eupenicillium shearii* - I. Taxonomy, fermentation, isolation and biological properties. *J ANTIBIOT* 56:993-999 (2003).
- Lee JK, Jung HM, Kim SY: 1,8-dihydroxynaphthalene (DHN)-melanin biosynthesis inhibitors increase erythritol production in *Torula corallina*, and DHN-melanin inhibits erythrose reductase. *APPL ENVIRON MICROBIOL* 69:3427-3434 (2003).
- Liu Y, Simon JD: Isolation and biophysical studies of natural eumelanins: Applications of imaging technologies and ultrafast spectroscopy. *PIGM CELL RES* 16:606-618 (2003).
- Mieczkowski T: Assessing the potential of a "color effect" for hair analysis of 11-nor-9-carboxy- $\Delta^8(9)$ -tetrahydrocannabinol: Analysis of a large sample of hair specimens. *LIFE SCI* 74:463-469 (2003).
- Nutt JG: Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. *EXP NEUROL* 184:9-13 (2003).
- Ono C, Yamada M, Tanaka M: Absorption, distribution and excretion of C-14-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. *J PHARM PHARMACOL* 55:1647-1654 (2003).
- Porras MG, DeLoof A, Breuer M, Aréchiga H: Corazonin promotes tegumentary pigment migration in the crayfish *Procambarus clarkii*. *PEPTIDES* 24:1581-1589 (2003).
- Rollins DE, Wilkins DG, Krueger GG, Augsburg MP, Mizuno A, O'Neal C, Borges CR, Slawson MH: The effect of hair color on the incorporation of codeine into human hair. *J ANAL TOXICOL* 27:545-551 (2003).
- Siefferman L, Hill GE: Structural and melanin coloration indicate parental effort and reproductive success in male eastern bluebirds. *BEHAV ECOL* 14:855-861 (2003).
- Zecca L, Zucca FA, Wilms H, Sulzer D: Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. *TRENDS NEUROSCI* 26:578-580 (2003).

MELANOSOMES, MELANOCYTES & KERATINOCYTES

- Abdallah M, Abdel-Naser MB, Moussa MH, Assaf C, Orfanos CE: Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. *EUROPEAN J DERMATOLOGY* 13:548-552 (2003).
- Abdel-Wanis ME, Kawahara N: Skeletal disorders associated with skin pigmentation: a role of melatonin? *MED HYPOTHESES* 61:640-642 (2003).
- Alaibac M, Piaserico S, Rossi CR, Foletto M, Zacchello G, Carli P, Belloni-Fortina A: Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. *J AMER ACAD DERMATOL* 49:1020-1022 (2003).
- Andersson TPM, Sköld HN, Svensson SPS: Phosphoinositide 3-kinase is involved in *Xenopus* and *Labrus* melanophore aggregation. *CELL SIGNAL* 15:1119-1127 (2003).
- Bauer J, Garbe C: Risk estimation for malignant transformation of melanocytic nevi. *ARCH DERMATOL* 140:127 (2004).
- Beck AJ, Phillips J, Smith-Thomas L, Short RD, MacNeil S: Development of a plasma-polymerized surface suitable for the transplantation of keratinocyte-melanocyte cocultures for patients with vitiligo. *TISSUE ENG* 9:1123-1131 (2003).
- Blum A, Soyer HP, Garbe C, Kerl H, Rassner G, Hofmann-Wellenhof R: The dermoscopic classification of atypical melanocytic naevi (Clark naevi) is useful to discriminate benign from malignant melanocytic lesions. *BRIT J DERMATOL* 149:1159-1164 (2003).
- Brodsky MC: Melanocytoma or congenital optic disk pigmentation? *AMER J OPHTHALMOL* 137:208-209 (2004).
- Carli P, Palli D: Re: Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. *J NAT CANCER INST* 95:1801 (2003).
- Casoli V, Cario-André M, Costet P, Pain C, Taïeb A: Comparison of long-term survival of pigmented epidermal reconstructs cultured in vitro vs. xenografted on nude mice. *PIGM CELL RES* 17:87-92 (2004).
- Chakraborty AK, Funasaka Y, Araki K, Horikawa T, Ichihashi M: Evidence that the small GTPase Rab8 is involved in melanosome traffic and dendrite extension in B16 melanoma cells. *CELL TISSUE RES* 314:381-388 (2003).
- Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard JH, Sturm RA: Human melanoblasts in culture: Expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. *J INVEST DERMATOL* 121:1150-1159 (2003).
- Cracknell KPB, Grierson I, Hogg P, Appleton P, Pfeiffer N: Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies. *EXP EYE RES* 77:721-730 (2003).
- Desnos C, Schonn JS, Huet S, Tran VS, El Amraoui A, Raposo GA, Fanget I, Chapuis C, Ménasché G, deSaintBasile G, Petit C, Cribier S, Henry JP, Darchen F: Rab27A and its effector MyRIP link secretory granules to F-actin and control their motion towards release sites. *J CELL BIOL* 163:559-570 (2003).
- Durbin ML, Lundy KE, Morrell PL, Torres-Martinez CL, Clegg MT: Genes that determine flower color: the role of regulatory changes in the evolution of phenotypic adaptations. *MOL PHYLOGENET EVOL* 29:507-518 (2003).
- ElIbrahim E, Aractingi S, Allory Y, Borrini F, Dupuy A, Du villard P, Carosella ED, Avril F, Paul P: Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. *INT J CANCER* 108:243-250 (2004).
- Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, Leachman SA: Novel application of a fibrin cell block method to evaluate melanocytic cell populations. *PIGM CELL RES* 16:662-669 (2003).
- Frudakis T, Thomas M, Gaskin Z, Venkateswarlu K, Chandra KS, Ginjupalli S, Gunturi S, Natrajan S, Ponnuswamy VK, Ponnuswamy KN: Sequences associated with human iris pigmentation. *GENETICS* 165:2071-2083 (2003).
- Grichnik JM: Dermoscopy of melanocytic neoplasms - Sclerotic blue nevi. *ARCH DERMATOL* 139:1522 (2003).
- Grichnik JM: Dermoscopy of melanocytic neoplasms - Subpatterns of dysplastic/atypical nevi. *ARCH DERMATOL* 140:142 (2004).

- Hassan AS, Schulte KW, Ruzicka T, Megahed M: Linear arrangement of multiple deep penetrating nevi - Report of first case and review of literature. *ARCH DERMATOL* 139:1608-1610 (2003).
- Higuchi K, Kawashima M, Ichikawa Y, Imokawa G: Sphingosylphosphorylcholine is a melanogenic stimulator for human melanocytes. *PIGM CELL RES* 16:670-678 (2003).
- Hirobe T, Osawa M, Nishikawa SI: Steel factor controls the proliferation and differentiation of neonatal mouse epidermal melanocytes in culture. *PIGM CELL RES* 16:644-655 (2003).
- Hirobe T, Wakamatsu K, Ito S: Changes in the proliferation and differentiation of neonatal mouse pink-eyed dilution melanocytes in the presence of excess tyrosine. *PIGM CELL RES* 16:619-628 (2003).
- Hirobe T, Osawa M, Nishikawa S: Hepatocyte growth factor controls the proliferation of cultured epidermal melanoblasts and melanocytes from newborn mice. *PIGM CELL RES* 17:51-61 (2004).
- Holt JB, Sanguenza OP, Levine EA, Shen P, Bergman S, Geisinger KR, Creager AJ: Nodal melanocytic nevi in sentinel lymph nodes - Correlation with melanoma-associated cutaneous nevi. *AMER J CLIN PATHOL* 121:58-63 (2004).
- Hwang JS, Choi H, Rho HS, Shin HJ, Kim DH, Lee J, Lee BG, Chang I: Pigment-lightening effect of N,N&PRIME;-dilinoleylcystamine on human melanoma cells. *BRIT J DERMATOL* 150:39-46 (2004).
- Isoldi MC, Matioli SR, Castrucci AMD, DeLima LHRG, Visconti MA, Rebouças NA: Identification of protein kinase C (PKC) isoforms in teleostean, amphibian and avian pigment cells. *PIGM CELL RES* 16:639-643 (2003).
- Kim DS, Park SH, Kim SE, Kwon SB, Park ES, Youn SW, Park KC: Lysophosphatidic acid inhibits melanocyte proliferation via cell cycle arrest. *ARCH PHARM RESEARCH* 26:1055-1060 (2003).
- Leech SN, Bell H, Leonard N, Jones SL, Geurin D, McKee PH, Lawrence CM: Neonatal giant congenital nevi with proliferative nodules - A clinicopathologic study and literature review of neonatal melanoma. *ARCH DERMATOL* 140:83-88 (2004).
- Legg J, Jensen UB, Broad S, Leigh I, Watt FM: Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis. *DEVELOPMENT* 130:6049-6063 (2003).
- Loppnau P, Tanguay P, Breuil C: Isolation and disruption of the melanin pathway polyketide synthase gene of the softwood deep stain fungus *Ceratocystis resinifera*. *FUNGAL GENET BIOL* 41:33-41 (2004).
- Maniak M: Organelle transport: A park-and-ride system for melanosomes. *CURR BIOL* 13:R917-R919 (2003).
- Middelkamp-Hup MA, Pathak MA, Parrado C, Garcia-Caballero T, Rius-Díaz F, Fitzpatrick TB, González S: Orally ministered *Polypodium leucotomos* extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. *J AMER ACAD DERMATOL* 50:41-49 (2004).
- Naeyaert JM, Brochez L: Dysplastic nevi. *N ENGL J MED* 349:2233-2240 (2003).
- Nagata H, Takekoshi S, Takeyama R, Homma T, Osamura RY: Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes. *PIGM CELL RES* 17:66-73 (2004).
- Nascimento AA, Roland JT, Gelfand VI: Pigment cells: A model for the study of organelle transport. *ANNU REV CELL DEV BIOL* 19:469-491 (2003).
- Nijhout HF, Maini PK, Madzvamuse A, Wathen AJ, Sekimura T: Pigmentation pattern formation in butterflies: experiments and models. *C R BIOL* 326:717-727 (2003).
- O'Brien EK, d'Alençon C, Bonde G, Li W, Schoenebeck J, Allende ML, Gelb BD, Yelon D, Eisen JS, Cornell RA: Transcription factor *Ap-2α* is necessary for development of embryonic melanophores, autonomic neurons and pharyngeal skeleton in zebrafish. *DEVELOP BIOL* 265:246-261 (2004).
- Park HY, Lee J, González S, Middelkamp-Hup MA, Kapasi S, Peterson S, Gilchrist BA: Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. *J INVEST DERMATOL* 122:159-166 (2004).
- Parsad D, Pandhi R, Dogra S, Kumar B: Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. *J AMER ACAD DERMATOL* 50:63-67 (2004).
- Petersen AB, Na RH, Wulf HC: Sunless skin tanning with dihydroxyacetone delays broad-spectrum ultraviolet photocarcinogenesis in hairless mice. *MUTAT RES GENET TOXICOL E M* 542:129-138 (2003).
- Piris A, Rosai J: Pigmented lesions in unusual anatomic sites. *SEMIN DIAGN PATHOL* 20:249-259 (2003).
- Quatresooz P, Arrese JE, Pierard-Franchimont C, Pierard GE: Immunohistochemical aid at risk stratification of melanocytic neoplasms. *INT J ONCOL* 24:211-216 (2004).

- Rees JL: Genetics of hair and skin color. *ANNU REV GENET* 37:67-90 (2003).
- Rodionov V, Yi J, Kashina A, Oladipo A, Gross SP: Switching between microtubule- and actin-based transport systems in melanophores is controlled by cAMP levels. *CURR BIOL* 13:1837-1847 (2003).
- Sandby-Moller J, Poulsen T, Wulf HC: Epidermal thickness at different body sites: Relationship to age, gender, pigmentation, blood content, skin type and smoking habits. *ACTA DERMATO VENEREOL* 83:410-413 (2003).
- Sanusi ID: The histologic diagnosis of primary benign and malignant cutaneous melanocytic lesions. *J HISTOTECHNOL* 26:227-230 (2003).
- Schallreuter KU, Kothari S, Elwary S, Rokos H, Hasse S, Panske A: Molecular evidence that halo in Sutton's naevus is not vitiligo. *ARCH DERMATOL RES* 295:223-228 (2003).
- Singh AD, Rundle PA, Slater DN, Rennie IG, Parsons A, McDonagh AJG: Uveal and cutaneous involvement in paraneoplastic melanocytic proliferation. *ARCH OPHTHALMOL* 121:1637-1640 (2003).
- Slominski A, Pisarchik A, Tobin DJ, Mazurkiewicz JE, Wortsman J: Differential expression of a cutaneous corticotropin-releasing hormone system. *ENDOCRINOLOGY* 145:941-950 (2004).
- Stein MP, Dong JB, Wandinger-Ness A: Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. *ADVAN DRUG DELIVERY REV* 55:1421-1437 (2003).
- Suzuki I, Motokawa T: In situ hybridization: An informative technique for pigment cell researchers. *PIGM CELL RES* 17:10-14 (2004).
- Thiagalingam S, Wang JJ, Mitchell P: Absence of change in choroidal Nevi across 5 years in an older population. *ARCH OPHTHALMOL* 122:89-93 (2004).
- Torrelo A, DePrada I, Zambrano A, Happle R: Extensive speckled lentiginous nevus associated with giant congenital melanocytic nevus: an unusual example of twin spotting? *EUROPEAN J DERMATOLOGY* 13:534-536 (2003).
- Tosney KW: Long-distance cue from emerging dermis stimulates neural crest melanoblast migration. *DEVELOP DYNAM* 229:99-108 (2004).
- Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M: Imatinib mesylate causes hypopigmentation in the skin. *CANCER* 98:2483-2487 (2003).
- Tsao H, Bevona C, Goggins W, Quinn T: Risk estimation for malignant transformation of melanocytic nevi - Reply. *ARCH DERMATOL* 140:127 (2004).
- Våge DI, Fleet MR, Ponz R, Olsen RT, Monteagudo LV, Tejedor MT, Arruga MV, Gagliardi R, Postiglioni A, Natrass GS, Klungland H: Mapping and characterization of the dominant black colour locus in sheep. *PIGM CELL RES* 16:693-697 (2003).
- Wang X, Erf GF: Apoptosis in feathers of Smyth line chickens with autoimmune vitiligo. *J AUTOIMMUN* 22:21-30 (2004).
- Wellman G, Ma L, Nordberg ML: Molecular markers of melanocytic lesions. *J HISTOTECHNOL* 26:267-269 (2003).
- Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC: Re: Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma - Response. *J NAT CANCER INST* 95:1801-1802 (2003).
- Yamakoshi J, Otsuka F, Sano A, Tokutake S, Saito M, Kikuchi M, Kubota Y: Lightening effect on ultraviolet-induced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. *PIGM CELL RES* 16:629-638 (2003).
- Yu BD, Becker-Hapak M, Snyder EL, Deniscourt C, Dowdy SF: Distinct and nonoverlapping roles for pRB and cyclin D: cyclin-dependent kinases 4/6 activity in melanocyte survival. *PROC NAT ACAD SCI USA* 100:14881-14886 (2003).
- Zalaudek I, Argenziano G, Ferrara G, Soyer HP, Corona R, Sera F, Cerroni L, Carbone A, Chiominto A, Cicale L, DeRosa G, Ferrari A, Hofmann-Wellenhof R, Malvehy J, Peris K, Pizzichetta MA, Puig S, Scalvenzi M, Staibano S, Ruocco V: Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. *BRIT J DERMATOL* 150:64-71 (2004).
- Zhang H, Rosdahl I: Ultraviolet A and B differently induce intracellular protein expression in human skin melanocytes - a speculation of separate pathways in initiation of melanoma. *CARCINOGENESIS* 24:1929-1934 (2003).
- Zhang RZ, Zhu WY, Xia MY, Feng Y: Morphology of cultured human epidermal melanocytes observed by atomic force microscopy. *PIGM CELL RES* 17:62-65 (2004).

Zhou H, Cadigan KM, Thiele DJ: A copper-regulated transporter required for copper acquisition, pigmentation, and specific stages of development in *Drosophila melanogaster*. *J BIOL CHEM* 278:48210-48218 (2003).

MELANOMA & METASTASIS

- Abdel-Wahab Z, Kalady MF, Emami S, Onaitis MW, Abdel-Wahab OI, Cisco R, Wheless L, Cheng TY, Tyler DS, Pruitt SK: Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. *CELL IMMUNOL* 224:86-97 (2003).
- Adamina M, Bolli M, Albo F, Cavazza A, Zajac P, Padovan E, Schumacher R, Reschner A, Feder C, Marti WR, Oertli D, Heberer M, Spagnoli GC: Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. *BRIT J CANCER* 90:263-269 (2004).
- Agnese DM, Abdessalam SF, Burak WE, Magro CM, Pozderac RV, Walker MJ: Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. *SURGERY* 134:542-547 (2003).
- Aldrian S, Kindas-Mügge I, Trautinger F, Fröhlich I, Gsur A, Herbacek I, Berger W, Micksche M: Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system. *CELL STRESS CHAPERONES* 8:249-257 (2003).
- Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles - A tissue microarray-based study. *AMER J PATHOL* 164:193-203 (2004).
- Altman JF, Lowe L, Redman B, Esper P, Schwartz JL, Johnson TM, Haefner HK: Placental metastasis of maternal melanoma. *J AMER ACAD DERMATOL* 49:1150-1154 (2003).
- Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, Straten PT: Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. *SEMIN CANCER BIOL* 13:449-459 (2003).
- Arbiser JL: Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase). *J INVEST DERMATOL* 121:XIV (2003).
- Augsburger JJ: Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas - Discussion. *OPHTHALMOLOGY* 110:2215 (2003).
- Azemar M, Djahansouzi S, Jäger E, Solbach C, Schmidt M, Maurer AB, Mross K, Unger C, vonMinckwitz G, Dall P, Groner B, Wels WS: Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. *BREAST CANCER RES TREAT* 82:155-164 (2003).
- Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W: The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. *J SURG RES* 116:129-136 (2004).
- Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weillbaecher KN: Platelet and osteoclast $\beta\delta(3)$ integrins are critical for bone metastasis. *PROC NAT ACAD SCI USA* 100:14205-14210 (2003).
- Baron S, Goulden V, Stables G: Atypical melanoma. *J ROY SOC MED* 96:592-594 (2003).
- Bartlema YM, Oosterhuis JA, Journée-deKorver JG, Tjho-Heslinga RE, Keunen JEE: Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. *BRIT J OPHTHALMOL* 87:1370-1373 (2003).
- Bendre M, Gaddy D, Nicholas RW, Suva LJ: Breast cancer metastasis to bone - It is not all about PTHrP. *CLIN ORTHOP RELATED RES* :S39-S45 (2003).
- Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N: Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. *J IMMUNOL* 171:6283-6289 (2003).
- Benouchan M, DoNascimento F, Sebbah-Louriki M, Salzmann JL, Crépin M, Perret GY, Colombo BM: Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after *Escherichia coli* nitroreductase gene delivery. *BIOCHEM BIOPHYS RES COMMUN* 311:822-828 (2003).
- Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL: Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. *CANCER RES* 63:8103-8107 (2003).

- Bernsen MR, Diepstra JHS, vanMil P, Punt CAJ, Figdor CG, vanMuijen GNP, Adema GJ, Ruiter DJ: Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. *J PATHOL* 202:70-79 (2004).
- Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H: Cutaneous melanomas associated with nevi. *ARCH DERMATOL* 139:1620-1624 (2003).
- Blaumann HR, González SJ, Longhino J, Cruz GAS, Larrieu OAC, Bonomi MR, Roth BMC: Boron neutron capture therapy of skin melanomas at the RA-6 reactor: A procedural approach to beam set up and performance evaluation for upcoming clinical trials. *MED PHYS* 31:70-80 (2004).
- Bodei L, Hofland LJ, Ferone D, Mooy CM, Kros JM, Paridaens DA, Baarsma SG, Ferdeghini M, vanHagen MP, Krenning EP, Kwekkeboom DJ: In vivo and in vitro detection of dopamine D-2 receptors in uveal melanomas. *CANCER BIOTHER RADIOPHARM* 18:895-902 (2003).
- Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA: Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. *LAB INVEST* 83:1583-1594 (2003).
- Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, DeSanto C, Macino B, Marin O, Zanovello P: Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. *J IMMUNOL* 171:6396-6405 (2003).
- Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS: Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. *HUM GENE THER* 14:1777-1785 (2003).
- Brzozowski Z, Saczewski F, Gdaniec M: Synthesis, structural characterization and in vitro antitumor activity of 4-dimethylaminopyridinium (6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)methanides. *EUR J MED CHEM* 38:991-999 (2003).
- Bukur J, Malenica B, Huber C, Seliger B: Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. *HUM IMMUNOL* 64:1081-1092 (2003).
- Byrd KM, Wilson DC, Hoyler SS, Peck GL: Advanced presentation of melanoma in African Americans. *J AMER ACAD DERMATOL* 50:21-24 (2004).
- Cangemi G, Morandi B, D'Agostino A, Peri C, Conte R, Damonte G, Ferlazzo G, Biassoni R, Melioli G: IFN- α 2 mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. *INT IMMUNOL* 15:1415-1421 (2003).
- Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarrà G, Castiglia D, Budroni M, Rozzo C, Manca A, Lissia A, Carboni A, Petretto E, Satriano SMR, Botti G, Mantelli M, Ghiorzo P, Stratton IR, Tanda F, Palmieri G: BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: The Italian melanoma intergroup study. *J CLIN ONCOL* 22:286-292 (2004).
- Chang CC, Murphy SP, Ferrone S: Differential in vivo and in vitro HLA-G expression in melanoma cells: Potential mechanisms. *HUM IMMUNOL* 64:1057-1063 (2003).
- Chang ML, Chen YT, Su YC, Kung JT: Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma. *J BIOMED SCI* 10:644-650 (2003).
- Chen CN, Wu CL, Lin JK: Propolin C from propolis induces apoptosis through activating caspases, Bid and cytochrome C release in human melanoma cells. *BIOCHEM PHARMACOL* 67:53-66 (2004).
- Cheng TY, Grubbs E, Abdul-Wahab O, Leu SY, Hung CF, Petros W, Aloia T, Fedrau R, Pruitt S, Colvin M, Friedman H, Tyler D: Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. *AMER J SURG* 186:460-467 (2003).
- Chimenti S, Carrozzo AM, Citarella L, DeFelice C, Peris K: Treatment of lentigo maligna with tazarotene 0.1% gel. *J AMER ACAD DERMATOL* 50:101-103 (2004).
- Choi C, Kusewitt DF: Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. *VET PATHOL* 40:713-718 (2003).
- Chou FI, Chung HP, Shieh MS, Huang CW, Chung RJ, Liu HM, Yang JY, Chi CW, Lin YC, Lu WY, Ka JJ: Synthesis and in vitro evaluation of the phenylboric acid derivative entrapped lipiodol in boron neutron capture therapy for hepatoma. *ANTICANCER RES* 23:3955-3963 (2003).

- Chung KH, Kim SH, Han KY, Sohn YD, Kim DS, Jang Y, Kim DS, Kang IC: Inhibitory effect of salmosin, a Korean snake venom-derived disintegrin, on the integrin $\alpha 5(\nu)$ -mediated proliferation of SK-Mel-2 human melanoma cells. *J PHARM PHARMACOL* 55:1577-1582 (2003).
- Cobben DCP, Jager PL, Elsinga PH, Maas B, Suurmeijer AJH, Hoekstra HJ: 3'-F-18-fluoro-3'-deoxy-L-thymidine: A new tracer for staging metastatic melanoma? *J NUCL MED* 44:1927-1932 (2003).
- Corona R: Cutaneous melanomas associated with nevi - Editors comment. *ARCH DERMATOL* 139:1624 (2003).
- Coss RA, Storck CW, Wachsberger PR, Reilly J, Leeper DB, Berd D, Wahl ML: Acute extracellular acidification reduces intracellular pH, 42°C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7. *INT J HYPEROTHERM* 20:93-106 (2004).
- Crocetti E, Carli P: Only superficial spreading melanoma is causing the melanoma epidemics? *EUR J EPIDEMIOL* 19:91-92 (2004).
- Cruz J, Reis JS, Lopes JM: Malignant peripheral nerve sheath tumour-like primary cutaneous malignant melanoma. *J CLIN PATHOL* 57:218-220 (2004).
- Cuthbertson F, Luck J, Rose S: Malignant melanoma of the conjunctiva metastasising to the parotid gland. *BRIT J OPHTHALMOL* 87:1428-1429 (2003).
- Dadaglio G, Morel S, Bauche C, Moukrim Z, Lemonnier FA, VandenEynde BJ, Ladant D, Leclerc C: Recombinant adenylate cyclase toxin of *Bordetella pertussis* induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. *INT IMMUNOL* 15:1423-1430 (2003).
- DeGiorgi V, Massi D, Trez E, Alfaioli B, Carli P: Multiple pigmented trichoblastomas and syringocystadenoma papilliferum in naevus sebaceous mimicking a malignant melanoma: a clinical dermoscopic-pathological case study. *BRIT J DERMATOL* 149:1067-1070 (2003).
- DeGiorgi V, Massi D, Sestini S, Alfaioli B, Carli P: Elderly woman with rapidly growing, ulcerated pigmented lesion. *CAN MED ASSN J* 169:1054 (2003).
- Deichmann M, Kahle B, Benner A, Thome M, Helmke B, Näher H: Somatic mitochondrial mutations in melanoma resection specimens. *INT J ONCOL* 24:137-141 (2004).
- Delaney YM, Hague S, McDonald B: Aggressive primary orbital melanoma in a young white man with no predisposing ocular features. *ARCH OPHTHALMOL* 122:118-121 (2004).
- DeLasCasas LE, Gokden M, Baker SJ, Korourian S, Hermonat PL, You H, Miranda RN, Shalkharn JE, O'Brien LA, Mukunyadzi P: Malignant melanoma metastatic to the liver - A cytomorphologic comparative study to identify reproducible diagnostic criteria. *ACTA CYTOL* 48:32-38 (2004).
- DelBufalo D, Trisciuglio D, Scarsella M, Zangemeister-Wittke U, Zupi G: Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. *ONCOGENE* 22:8441-8447 (2003).
- Delfgaauw J, Duschl J, Wellbrock C, Froschauer C, Schartl M, Altschmied J: MITF-M plays an essential role in transcriptional activation and signal transduction in Xiphophorus melanoma. *GENE* 320:117-126 (2003).
- Dennis LK, Freeman LEB, VanBeek MJ: Sunscreen use and the risk for melanoma: A quantitative review. *ANN INTERN MED* 139:966-978 (2003).
- Dezfouli S, Hatzinisiriou I, Ralph SJ: Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFN η primed and IFN β treated B7-1(+)B16-F10 melanoma cells. *IMMUN CELL BIOL* 81:459-471 (2003).
- Dissemond J, Busch M, Kothen T, Mörs J, Weimann TK, Lindeke A, Goos M, Wagner SN: Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. *CANCER LETT* 203:225-231 (2004).
- Domingo E, Espín E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz S: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. *GENE CHROMOSOME CANCER* 39:138-142 (2004).
- Donnelly J: Cancer vaccine targets leukemia. *NATURE MED* 9:1354-1356 (2003).
- Dressel R, Grzeszik C, Kreiss M, Lindemann D, Herrmann T, Walter L, Günther E: Differential effect of acute and permanent heat shock protein 70 overexpression in tumor cells on lysability by cytotoxic T lymphocytes. *CANCER RES* 63:8212-8220 (2003).
- Dummer R: About moles, melanomas, and lasers - The dermatologist's schizophrenic attitude toward pigmented lesions. *ARCH DERMATOL* 139:1405-1406 (2003).

- Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE, Geilen CC: CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. *ONCOGENE* 22:9131-9141 (2003).
- Ehlken H, Schadendorf D, Eichmüller S: Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. *INT J CANCER* 108:307-313 (2004).
- Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. *CANCER RES* 63:8330-8337 (2003).
- English DR, DelMar CB, Burton RC: Diagnosing pigmented skin lesions in general practice - Objective assessment of skin lesions is possible - Reply. *BRIT MED J* 327:1167-1168 (2003).
- Esmaeli B, Reifler D, Prieto VG, Ahmadi MA, Hidaji L, Delpassand E, Ross MI: Conjunctival melanoma with a positive sentinel lymph node. *ARCH OPHTHALMOL* 121:1779-1783 (2003).
- Eves P, Haycock J, Layton C, Wagner M, Kemp H, Szabo M, Morandini R, Ghanem G, García-Borrón JC, Jiménez-Cervantes C, MacNeil S: Anti-inflammatory and anti-invasive effects of $\alpha\delta$ -melanocyte-stimulating hormone in human melanoma cells. *BRIT J CANCER* 89:2004-2015 (2003).
- Eves P, Katerinaki E, Simpson C, Layton C, Dawson R, Evans G, MacNeil S: Melanoma invasion in reconstructed human skin is influenced by skin cells investigation of the role of proteolytic enzymes. *CLIN EXP METASTAS* 20:685-700 (2003).
- Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF, O'Brien JC, Kuhn JA: Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. *AMER J SURG* 186:675-681 (2003).
- Finger PT, Yu GP: Conjunctival melanoma: Is it increasing in the United States? *AMER J OPHTHALMOL* 136:1190-1191 (2003).
- Fleischer K, Schmidt B, Kastenmüller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H: Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. *J IMMUNOL* 172:162-169 (2004).
- Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN: A gallium-labeled DOTA- $\alpha\delta$ -melanocyte-stimulating hormone analog for PET Imaging of melanoma metastases. *J NUCL MED* 45:116-123 (2004).
- Gatta G, Capocaccia R, DeAngelis R, Stiller C, Coebergh JW: Cancer survival in European adolescents and young adults. *EUR J CANCER* 39:2600-2610 (2003).
- Gazagne A, Claret E, Wijdenes J, Yssel H, Bousquet F, Levy E, Vielh P, Scotte F, LeGoupil T, Fridman WH, Tartour E: A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. *J IMMUNOL METHOD* 283:91-98 (2003).
- Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R: Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4(+) and CD8(+) T cell immunity against B16 melanoma. *J IMMUNOL* 171:5940-5947 (2003).
- Gonzalez-Gomez P, Bello MJ, Alonso ME, Amiñoso C, Lopez-Marin I, DeCampos JM, Isla A, Gutierrez M, Rey JA: Promoter methylation status of multiple genes in brain metastases of solid tumors. *INT J MOL MED* 13:93-98 (2004).
- Guérin S, Dupuy A, Anderson H, Shamsaldin A, Svahn-Tapper G, Moller T, Quiniou E, Garwicz S, Hawkins M, Avril MF, Oberlin O, Chavaudra J, deVathaire F: Radiation dose as a risk factor for malignant melanoma following childhood cancer. *EUR J CANCER* 39:2379-2386 (2003).
- Guerrera M, Ladisch S: N-Butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. *CANCER LETT* 201:31-40 (2003).
- Gun RT, Pratt NL, Griffith EC, Adams GG, Bisby JA, Robinson KL: Update of a prospective study of mortality and cancer incidence in the Australian petroleum industry. *OCCUP ENVIRON MEDICINE* 61:150-156 (2004).
- Hadden PW, Hiscott PS, Damato BE: Histopathology of eyes enucleated after endoresection of choroidal melanoma. *OPHTHALMOLOGY* 111:154-160 (2004).
- Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M, Vogt T: Loss of EphB6 expression in metastatic melanoma. *INT J ONCOL* 23:1553-1559 (2003).

- Hanada T, Toshinai K, Date Y, Kajimura N, Tsukada T, Hayashi Y, Kangawa K, Nakazato M: Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. *METABOLISM* 53:84-88 (2004).
- Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M: Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. *J CLIN ONCOL* 22:53-61 (2004).
- Harbour JW, Brantley MA, Hollingsworth H, Gordon M: Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi. *BRIT J OPHTHALMOL* 88:36-38 (2004).
- Harbour JW, Brantley MA, Hollingsworth H, Gordon M: Association between choroidal pigmentation and posterior uveal melanoma in a white population. *BRIT J OPHTHALMOL* 88:39-43 (2004).
- Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V: Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. *CANCER RES* 63:8408-8413 (2003).
- Hernando JJ, Park TW, Kuhn WC: Dendritic cell-based vaccines in breast and gynaecologic cancer. *ANTICANCER RES* 23:4293-4303 (2003).
- Herrera GA: The search for an accurate pathologic assessment of melanoma: Where do we stand today? *J HISTOTECHNOL* 26:211-212 (2003).
- Herrera GA: Metastatic melanoma: Ancillary diagnostic techniques. *J HISTOTECHNOL* 26:217-224 (2003).
- Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, Lett M: Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. *CANCER IMMUNOL IMMUNOTHER* 53:125-134 (2004).
- Hiramoto JS, Tsung K, Bedolli M, Norton JA, Hirose R: Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon- $\eta\delta$ and interleukin-12. *J SURG RES* 116:64-69 (2004).
- Hiscott P, Campbell RJ, Robertson DM, Damato B: Intraocular melanocytoma in association with bone formation. *ARCH OPHTHALMOL* 121:1791-1794 (2003).
- Hofbauer GFL, Burkhart A, Schüler G, Dummer R, Burg G, Nestle FO: High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. *J IMMUNOTHER* 27:73-78 (2004).
- Hofmann UB, Eggert AAO, Blass K, Bröcker EB, Becker JC: Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. *CANCER RES* 63:8221-8225 (2003).
- Hogan KT, Coppola MA, Gatlin CL, Thompson LW, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL, Ross MM: Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. *IMMUNOL LETT* 90:131-135 (2003).
- Höglund M, Gisselsson D, Hansen GB, White VA, Säll T, Mitelman F, Horsman D: Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution. *INT J CANCER* 108:57-65 (2004).
- Hörig H, Kaufmann HL: Local delivery of poxvirus vaccines for melanoma. *SEMIN CANCER BIOL* 13:417-422 (2003).
- Howell WM, Turner SJ, Theaker JM, Bateman AC: Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. *EUR J IMMUNOGENET* 30:409-414 (2003).
- Hsueh EC, Morton DL: Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. *SEMIN CANCER BIOL* 13:401-407 (2003).
- Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL: Prolonged survival after complete resection of metastases from intraocular melanoma. *CANCER* 100:122-129 (2004).
- Hu L, Sham JST, Tjia WM, Tan YQ, Lu GX, Guan XY: Generation of a complete set of human telomeric band painting probes by chromosome microdissection. *GENOMICS* 83:298-302 (2004).
- Hu WP, Wang JJ, Huang SM, Hein SY: Involvement of cytotoxicity and variation of the mitochondrial membrane potential induced by hybrid agent. *DRUG DEVELOP RES* 61:1-5 (2004).
- Huang JH, Asawa T, Takato T, Sakai R: Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma. *J BIOL CHEM* 278:48367-48376 (2003).

- Humzah MD: Diagnosing pigmented skin lesions in general practice - Objective assessment of skin lesions is possible. *BRIT MED J* 327:1167 (2003).
- Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei DQ, Furcht LT, McCarthy JB: Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. *J INVEST DERMATOL* 122:167-176 (2004).
- Irie RF, Ollila DW, O'Day S, Morton DL: Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. *CANCER IMMUNOL IMMUNOTHER* 53:110-117 (2004).
- Ishitsuka R, Yamaji-Hasegawa A, Makino A, Hirabayashi Y, Kobayashi T: A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes. *BIOPHYS J* 86:296-307 (2004).
- Ito A, Matsuoka F, Honda H, Kobayashi T: Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. *CANCER IMMUNOL IMMUNOTHER* 53:26-32 (2004).
- Johnson LA, Vaidya SV, Goldfar RH, Mathew PA: 2B4(CD244)-mediated activation of NK cells reduces metastases of B16F10 melanoma in mice. *ANTICANCER RES* 23:3651-3655 (2003).
- Johnson TM, Bradford CR, Gruber SB, Sondak VK, Schwartz JL: Staging workup, sentinel node biopsy, and follow-up tests for melanoma - Update of current concepts. *ARCH DERMATOL* 140:107-113 (2004).
- Jonas JB, Berenshtein E, Holbach L: Anatomic relationship between lamina cribrosa, intraocular space, and cerebrospinal fluid space. *INVEST OPHTHALMOL VISUAL SCI* 44:5189-5195 (2003).
- Jourdiar TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P: Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). *GENE THERAPY* 10:2126-2132 (2003).
- Kabalka GW, Yao ML: Synthesis of a potential boron neutron capture therapy agent: 1-aminocyclobutane-1-carboxylic acid bearing a butylboronic acid side chain. *SYNTHESIS STUTTGART* :2890-2893 (2003).
- Kakuta H, Tanatani A, Nagasawa K, Hashimoto Y: Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3&IT;H&IT;)-quinazolinedione skeleton. *CHEM PHARM BULL TOKYO* 51:1273-1282 (2003).
- Kampalath B, Abed N, Chitambar C, vanTuinen P, Chakrabarty G, Hanson G, Rao RN, Shidham V, Chang CC: Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: A diagnostic and treatment dilemma. *LEUK LYMPHOMA* 45:409-414 (2004).
- Kazubskaya TP, Kozlova VM, Musatov VK, Mikhailovskii AV, Shabanov MA, Trofimov EI, Sel'chuk VY, Garkavtseva RF: Identification of hereditary variants of cutaneous melanoma. *RUSS J GENET* 40:74-80 (2004).
- Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A: Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. *J IMMUNOL* 171:6251-6259 (2003).
- Kiebert GM, Jonas DL, Middleton MR: Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine. *CANCER INVEST* 21:821-829 (2003).
- Kim DS, Jeon SE, Park KC: Oxidation of indole-3-acetic acid by horseradish peroxidase induces apoptosis in G361 human melanoma cells. *CELL SIGNAL* 16:81-88 (2004).
- Kim YC, Lee MG, Cho SH, Lee JH, Lee DH, Ahn BK: The relation between p53 expression and physical site of melanoma: an immunohistochemical study. *BRIT J DERMATOL* 149:1299-1300 (2003).
- Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-ya M, Gojo S, Cui F, Ueda Y, Yamagishi H, Imanishi J, Mazda O: Electrochemo-gene therapy of cancer: Intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. *MOL THER* 8:738-745 (2003).
- Kolárová H, Mosinger J, Lenobel R, Kejllová K, Jírová D, Strnad M: In vitro toxicity testing of supramolecular sensitizers for photodynamic therapy. *TOXICOL VITRO* 17:775-778 (2003).
- Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W: Expression of RhoC is associated with metastasis of gastric carcinomas. *PATHOBIOLOGY* 71:19-25 (2004).
- Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, Spuzic I: IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon- α and DTIC. *CLIN EXP METASTAS* 20:647-655 (2003).

- Koyama S: Differential expression of intracellular apoptotic signaling molecules in tumor and tumor-infiltrating lymphocytes during development of invasion and/or metastasis of gastric carcinoma. *DIGEST DIS SCI* 48:2290-2300 (2003).
- Krone B, Kölmel KF, Grange JM, Mastrangelo G, Henz BM, Botev IN, Niin M, Seebacher C, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A: Impact of vaccinations and infectious diseases on the risk of melanoma - evaluation of an EORTC case-control study. *EUR J CANCER* 39:2372-2378 (2003).
- Kujala E, Mäkitie T, Kivelä T: Very long-term prognosis of patients with malignant uveal melanoma. *INVEST OPHTHALMOL VISUAL SCI* 44:4651-4659 (2003).
- Kumar R, Angelini S, Hemminki K: Activating BRAF and N-&IT;Ras&IT; mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. *ONCOGENE* 22:9217-9224 (2003).
- Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun YP, Ozdemir A, Yi TL, Williams BR, Borden EC: Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: Greater potency of IFN- β compared with IFN- α 2. *J INTERFERON CYTOKINE RES* 23:745-756 (2003).
- Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC, Fisher PB: Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. *ONCOGENE* 22:8758-8773 (2003).
- Lebedeva IV, Su ZZ, Sarkar D, Kitada S, Dent P, Waxman S, Reed JC, Fisher PB: Melanoma differentiation associated gene-7, Mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. *CANCER RES* 63:8138-8144 (2003).
- Lefevre G, Calipel A, Mouriaux F, Hecquet C, Malecaze F, Mascarelli F: Opposite long-term regulation of c-Myc and p27(Kip1) through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. *ONCOGENE* 22:8813-8822 (2003).
- Litvak DA, Gupta RK, Yee R, Wanek LA, Ye W, Morton DL: Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors. *J AMER COLL SURGEONS* 198:27-35 (2004).
- Liu T, Brouha B, Grossman D: Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. *ONCOGENE* 23:39-48 (2004).
- Liu YY, Cheung LH, Hittelman WN, Rosenblum MG: Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. *MOL CANCER THER* 2:1341-1350 (2003).
- Liu YY, Cheung LH, Marks JW, Rosenblum MG: Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. *INT J CANCER* 108:549-557 (2004).
- Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, Luciani F, Lugini L, Federici C, Ramoni C, Rivoltini L, Parmiani G, Belardelli F, Rivera P, Marcenaro S, Moretta L, Fais S: Effect of human natural killer and η T cells on the growth of human autologous melanoma xenografts in SCID mice. *CANCER RES* 64:378-385 (2004).
- Lucas ML, Heller R: IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. *DNA CELL BIOL* 22:755-763 (2003).
- Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, Rivoltini L, Castelli C, Tinari A, Piris A, Parmiani G, Fais S: Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: A key role of ezrin. *LAB INVEST* 83:1555-1567 (2003).
- Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC: Determinants of BRAF mutations in primary melanomas. *J NAT CANCER INST* 95:1878-1880 (2003).
- Marchetti D, Aucoin R, Blust J, Murry B, Greiter-Wilke A: p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. *J CELL BIOCHEM* 91:206-215 (2004).
- Marincola FM, Ferrone S: Immunotherapy of melanoma: the good news, the bad ones and what to do next. *SEMIN CANCER BIOL* 13:387-389 (2003).
- Matsuda H, Morikawa T, Oda M, Asao Y, Yoshikawa M: Potent anti-metastatic activity of dimeric sesquiterpene thioalkaloids from the rhizome of *Nuphar pumilum*. *BIOORG MEDICINAL CHEM LETTER* 13:4445-4449 (2003).
- McGovern V: Digital diagnosis: New tool for detecting skin cancer. *ENVIRON HEALTH PERSPECT* 111:A770-A773 (2003).

- McLaren BK, Ma L: Desmoplastic malignant melanoma: Exposing the great masquerade. *J HISTOTECHNOL* 26:245-251 (2003).
- McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN: Treatment of brain metastases from melanoma. *MAYO CLIN PROC* 78:1529-1536 (2003).
- Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR: Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. *J BIOL CHEM* 279:1562-1569 (2004).
- Mendoza L, Valcárcel M, Carrascal T, Egilegor E, Salado C, Sim BKL, Vidal-Vanaclocha F: Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. *CANCER RES* 64:304-310 (2004).
- Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, Pingpank JF, Sehgal CS, Yodh AG, Buerk DG, Fraker DL: An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. *CANCER RES* 63:7232-7240 (2003).
- Midena E, Pilotto E, deBelvis V, Zaltron S, Doro D, Segato T, Piermarocchi S: Choroidal vascular changes after transpupillary thermotherapy for choroidal melanoma. *OPHTHALMOLOGY* 110:2216-2222 (2003).
- Mihic-Probst D, Saremaslani P, Komminoth P, Heitz PU: Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. *VIRCHOWS ARCHIV* 443:745-751 (2003).
- Miller AJ, Du JY, Rowan S, Hershey CL, Widlund HR, Fisher DE: Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. *CANCER RES* 64:509-516 (2004).
- Mocellin S, Rossi CR, Nitti D, Lise M, Marincola FM: Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. *BBA REV CANCER* 1653:61-71 (2003).
- Monsurrò V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM: Active-specific immunization against melanoma: Is the problem at the receiving end? *SEMIN CANCER BIOL* 13:473-480 (2003).
- Moredock S, Nairn RS, Johnston DA, Byrom M, Heaton G, Lowery M, Mitchell DL: Mechanisms underlying DNA damage resistance in a Xiphophorus melanoma cell line. *CARCINOGENESIS* 24:1967-1975 (2003).
- Moschos SJ, Kirkwood JM, Konstantinopoulos PA: Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b. *J CLIN ONCOL* 22:11-14 (2004).
- Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C: Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. *CYTOKINES CELL MOL THER* 7:151-156 (2002).
- Munz DL: Reconfirmation of clinical unpredictability of lymphatic drainage in cutaneous melanoma and new developments in sentinel lymph node diagnostics. *J NUCL MED* 44:1871 (2003).
- Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST: Immune evasion by murine melanoma mediated through CC chemokine receptor-10. *J EXP MED* 198:1337-1347 (2003).
- Murray CA, Leong WL, McCready DR, Ghazarian DM: Histopathological patterns of melanoma metastases in sentinel lymph nodes. *J CLIN PATHOL* 57:64-67 (2004).
- Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, Födinger D, Seppel H, Schanab O, Magin-Lachmann C, Löwer R, Jansen B, Pehamberger H, Wolff K: An endogenous retrovirus derived from human melanoma cells. *CANCER RES* 63:8735-8741 (2003).
- Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, Kogo M: Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. *GENES CELLS* 8:1019-1027 (2003).
- Nakajima A, Kataoka K, Hong M, Sakaguchi M, Huh N: BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. *CANCER LETT* 201:195-201 (2003).
- Nakamura K, Konoha K, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M: Combined effects of Cordyceps sinensis and methotrexate on hematogenic lung metastasis in mice. *RECEPT CHANNEL* 9:329-334 (2003).
- Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL: Treatment of lentigo maligna with topical imiquimod. *BRIT J DERMATOL* 149:66-69 (2003).

- Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, Kontermann RE, Alemany R, Curiel DT: Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. *INT J CANCER* 108:136-145 (2004).
- Ntayi C, Hornebeck W, Bernard P: Influence of cultured dermal fibroblasts on human melanoma cell proliferation, matrix metalloproteinase-2 (MMP-2) expression and invasion in vitro. *ARCH DERMATOL RES* 295:236-241 (2003).
- Oka H, Sasaki H, Shiraishi Y, Emori Y, Yoshinaga K, Takei M: Z-100, an immunomodulatory arabinomannan extracted from *Mycobacterium tuberculosis* strain aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1 T cell responses. *BIOL PHARM BULL* 27:82-88 (2004).
- Pache M, Glatz K, Bösch D, Dirnhofer S, Mirlacher M, Simon R, Schraml P, Ruffle A, Flammer J, Sauter G, Meyer P: Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. *VIRCHOWS ARCHIV* 443:741-744 (2003).
- Page RN, King R, Googe PB: Tissue microarray in melanoma. *J HISTOTECHNOL* 26:271-274 (2003).
- Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, Kerbel RS, Ben David Y: Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. *ONCOGENE* 23:30-38 (2004).
- Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. *J IMMUNOL* 172:1582-1587 (2004).
- Pappo AS: Melanoma in children and adolescents. *EUR J CANCER* 39:2651-2661 (2003).
- Parker CJ, Shawcross SG, Li HG, Wang QY, Herrington CS, Kumar S, MacKie RM, Prime W, Rennie IG, Sisley K, Kumar P: Expression of PAX 3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin. *INT J CANCER* 108:314-320 (2004).
- Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M: Immunotherapy of melanoma. *SEMIN CANCER BIOL* 13:391-400 (2003).
- Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL: Fine mapping of chromosome 3 in uveal melanoma: Identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. *CANCER RES* 63:8507-8510 (2003).
- Perez-Gomez B, Pollán M, Gustavsson P, Plato N, Aragonés N, López-Abente G: Cutaneous melanoma: hints from occupational risks by anatomic site in Swedish men. *OCCUP ENVIRON MEDICINE* 61:117-126 (2004).
- Pochec E, Litynska A, Amoresano A, Casbarra A: Glycosylation profile of integrin $\alpha(3)\beta(1)$ changes with melanoma progression. *BBA MOL CELL RES* 1643:113-123 (2003).
- Poláková K, Bandzuchová E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. *NEOPLASMA* 50:331-338 (2003).
- Poser I, Bosserhoff AK: Transcription factors involved in development and progression of malignant melanoma. *HISTOL HISTOPATHOL* 19:173-188 (2004).
- Postovit LM, Adams MA, Lash GE, Heaton JPW, Graham CH: Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. *INT J CANCER* 108:47-53 (2004).
- Potti A, Hille R, Koch M: Immunohistochemical determination of HER-2/neu in malignant melanoma. *ANTICANCER RES* 23:4067-4069 (2003).
- Potti A, Moazzam N, Tendulkar K, Javed NA, Koch M, Kargas S: Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. *ANTICANCER RES* 23:4023-4026 (2003).
- Powell DJ, Rosenberg SA: Phenotypic and functional maturation of tumor antigen-reactive CD8(+) T lymphocytes in patients undergoing multiple course peptide vaccination. *J IMMUNOTHER* 27:36-47 (2004).
- Prekuc S, Svedruzic D, Gazivoda T, Mrvos-Sermek D, Nagl A, Grdisa M, Pavelic K, Balzamin J, DeClercq E, Folkers G, Scapozza L, Mintas M, Raic-Malic S: Synthesis and biological evaluation of iodinated and fluorinated 9-(2-hydroxypropyl) and 9-(2-hydroxyethoxy)methyl purine nucleoside analogues. *J MED CHEM* 46:5763-5772 (2003).
- Prins RM, Odesa SK, Liao LM: Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. *CANCER RES* 63:8487-8491 (2003).

- Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T: Iodine Brachytherapy as an alternative to enucleation for large uveal melanomas. *OPHTHALMOLOGY* 110:2223-2234 (2003).
- Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. *BRIT J CANCER* 89:1620-1626 (2003).
- Radosevich TJ, Seregina T, Link CJ: Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon- η exposure. *HUM GENE THER* 14:1765-1775 (2003).
- Ramont L, Pasco S, Hornebeck W, Maquart FX, Monboisse JC: Transforming growth factor- β 1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. *EXP CELL RES* 291:1-10 (2003).
- Ready N, Weinstock MA: Adjuvant high-dose interferon therapy for high-risk melanoma. *ARCH DERMATOL* 139:1635-1637 (2003).
- Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH: Hla-B35-restricted immune responses against survivin in cancer patients. *INT J CANCER* 108:937-941 (2004).
- Ridgway D: The first 1000 dendritic cell vaccinees. *CANCER INVEST* 21:873-886 (2003).
- Riteau B, Faure F, Menier C, Viel S, Carosella ED, Amigorena S, Rouas-Freiss N: Exosomes bearing HLA-G are released by melanoma cells. *HUM IMMUNOL* 64:1064-1072 (2003).
- Robson A, Morley-Quante M, Hempel H, McKee PH, Calonje E: Deep penetrating naevus: clinicopathological study of 31 cases with further delineation of histological features allowing distinction from other pigmented benign melanocytic lesions and melanoma. *HISTOPATHOLOGY* 43:529-537 (2003).
- Rofstad EK, Mathiesen B, Galappathi K: Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: Radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. *CANCER RES* 64:13-18 (2004).
- Rosien F, Haacke TC, Hauschild A: Amelanotic malignant melanoma of the scalp resembling a proliferative trichilemmal cyst. *DEUT MED WOCHENSCHR* 128:2360-2362 (2003).
- Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. *CELL MOL LIFE SCI* 61:118-128 (2004).
- Rousseau P, LeDiscorde M, Mouillot G, Marcou C, Carosella ED, Moreau P: The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. *HUM IMMUNOL* 64:1005-1010 (2003).
- Rousselet N, Mills L, Jean D, Tellez C, Bar-Eli M, Frade R: Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. *CANCER RES* 64:146-151 (2004).
- Ruf P, Jäger M, Ellwart J, Wosch S, Kusterer E, Lindhofer H: Two new trifunctional antibodies for the therapy of human malignant melanoma. *INT J CANCER* 108:725-732 (2004).
- Salazar AM, Calderón-Aranda E, Cebrián ME, Sordo M, Bendesky A, Gómez-Muñoz A, Acosta-Saavedra L, Ostrosky-Wegman P: p53 expression in circulating lymphocytes of non-melanoma skin cancer patients from an arsenic contaminated region in Mexico. A pilot study. *MOL CELL BIOCHEM* 255:25-31 (2004).
- Sant VP, Nagarsenker MS, Rao SGA, Gude RP: Sterically stabilized etoposide liposomes: Evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice. *CANCER BIOTHER RADIOPHARM* 18:811-817 (2003).
- Sanz-Trelles A, Arranz-Salas IM, Valenzuela-Serrano MI: Melanoma arising in and limited to a spinal nerve root of the cauda equina. *HISTOPATHOLOGY* 43:603-604 (2003).
- Sarosi LAG, Rieber MS, Rieber M: Hydrogen peroxide increases a 55-kDa tyrosinase concomitantly with induction of p53-dependent p21 waf1 expression and a greater Bax/Bcl-2 ratio in pigmented melanoma. *BIOCHEM BIOPHYS RES COMMUN* 312:355-359 (2003).
- Schiltz PM, Dillman RO: Serum cytokines in metastatic melanoma patients treated with an autologous tumor vaccine. *CANCER BIOTHER RADIOPHARM* 18:879-886 (2003).
- Schmiegl J, Yang GL, Franck RW, Tsuji M: Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α - δ -galactosylceramide. *J EXP MED* 198:1631-1641 (2003).

- Schneeberger A, Lührs P, Kutil R, Steinlein P, Schild H, Schmidt W, Stingl G: Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells. *J IMMUNOL* 171:5180-5187 (2003).
- Schöder H, Larson SM, Yeung HWD: PET/CT in oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. *J NUCL MED* 45:72S-81S (2004).
- Schuchter LM: Adjuvant interferon therapy for melanoma: High-dose, low-dose, no dose, which dose? *J CLIN ONCOL* 22:7-10 (2004).
- Scolyer RA, Shaw HM, Thompson JF, Li LXL, Colman MH, Lo SK, McCarthy SW, Palmer AA, Nicoll KD, Dutta B, Slobedman E, Watson GF, Stretch JR: Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. *AMER J SURG PATHOL* 27:1571-1576 (2003).
- Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemans K, vanderBruggen P, Schuler G: Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. *J IMMUNOL* 172:1304-1310 (2004).
- Shen HB, Liu ZS, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei QY: P53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. *J INVEST DERMATOL* 121:1510-1514 (2003).
- Shin JJ, Katayama T, Michaud WA, Rocco JW: Short hairpin RNA system to inhibit human p16 in squamous cell carcinoma. *ARCH OTOLAR HEAD NECK SURGERY* 130:68-73 (2004).
- Simon R: Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. *BRIT J CANCER* 89:1599-1604 (2003).
- Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EMH, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. *J CLIN ONCOL* 21:4016-4026 (2003).
- Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with α D-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. *J CLIN ONCOL* 21:4292-4298 (2003).
- Smith LH, Danielsen B, Allen ME, Cress R: Cancer associated with obstetric delivery: Results of linkage with the California cancer registry. *AMER J OBSTET GYNECOL* 189:1128-1135 (2003).
- Sommerer F, Vieth M, Markwarth A, Röhrich K, Vomschloss S, May A, Ell C, Stolte M, Hengge UR, Wittekind C, Tannapfel A: Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. *ONCOGENE* 23:554-558 (2004).
- Sondak VK, Sosman JA: Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine(R). *SEMIN CANCER BIOL* 13:409-415 (2003).
- Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P: Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. *SEMIN CANCER BIOL* 13:461-472 (2003).
- Spencer WH, Chan CC, Shen D, Rao NA: Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome. *ARCH OPHTHALMOL* 121:1551-1555 (2003).
- Stratas BA: Conjunctival melanoma: Is it increasing in the United States? *AMER J OPHTHALMOL* 136:1190 (2003).
- Strauss SJ, Marples M, Napier MP, Meyer T, Boxall J, Rustin GJS: A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. *BRIT J CANCER* 89:1901-1905 (2003).
- Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA: A phase II trial of temozolomide and IFN- α 2 in patients with advanced renal cell carcinoma. *J INTERFERON CYTOKINE RES* 24:37-41 (2004).
- Swetter SM, Ecker PM, Johnson DL, Harvell JD: Primary dermal melanoma - A distinct subtype of melanoma. *ARCH DERMATOL* 140:99-103 (2004).
- Taatjes DJ, Pang YJ, vonTurkovich M, DeLance N, Cooper K: Ultrastructural localization of diagnostically relevant melanoma-specific antibodies by immunoelectron microscopy. *J HISTOTECHNOL* 26:263-266 (2003).

- Taback B, O'Day SJ, Boasberg PD, Shu S, Fournier P, Elashoff R, Wang HJ, Hoon DSB: Circulating DNA microsatellites: Molecular determinants of response to biochemotherapy in patients with metastatic melanoma. *J NAT CANCER INST* 96:152-156 (2004).
- Talebi T, Weber JS: Peptide vaccine trials for melanoma: preclinical background and clinical results. *SEMIN CANCER BIOL* 13:431-438 (2003).
- Tang CH, Grimm EA: Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. *J BIOL CHEM* 279:288-298 (2004).
- Tang YW: Molecular diagnosis of atypical pneumonia. *ACTA PHARMACOL SIN* 24:1308-1313 (2003).
- Taylor JL, Maymí DMQ, Sporn TA, McAdam HP, Wahidi MM: Multiple lung nodules in a woman with a history of melanoma. *RESPIRATION* 70:544-548 (2003).
- Taylor SC: Advanced presentation of melanoma in African Americans. *J AMER ACAD DERMATOL* 50:142-143 (2004).
- Tellez C, McCarty M, Ruiz M, Bar-Eli M: Loss of activator protein-2 α results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. *J BIOL CHEM* 278:46632-46642 (2003).
- Terheyden P, Schrama D, Pedersen LO, Andersen MH, Kämpgen E, Straten PT, Becker JC: Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. *SCAND J IMMUNOL* 58:566-571 (2003).
- Toivonen P, Mäkitie T, Kujala E, Kivelä T: Microcirculation and tumor-infiltrating macrophages choroidal and ciliary body melanoma and corresponding metastases. *INVEST OPHTHALMOL VISUAL SCI* 45:1-6 (2004).
- Tomlinson R, Heller J, Brocchini S, Duncan R: Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. *BIOCONJUGATE CHEMISTRY* 14:1096-1106 (2003).
- Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W: Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. *ARCH DERMATOL* 140:67-70 (2004).
- Tsuchimochi M, Sakahara H, Hayama K, Funaki M, Ohno R, Shirahata T, Orskaug T, Maehlum G, Yoshioka K, Nygard E: A prototype small CdTe gamma camera for radioguided surgery and other imaging applications. *EUR J NUCL MED MOL IMAGING* 30:1605-1614 (2003).
- Tuomaala S, Kivelä T: Conjunctival melanoma: Is it increasing in the United States? *AMER J OPHTHALMOL* 136:1189-1190 (2003).
- Tuve S, Wagner SN, Schittek B, Pützner BM: Alterations of Δ TA-p73 splice transcripts during melanoma development and progression. *INT J CANCER* 108:162-166 (2004).
- Uren RF, Howman-Giles R, Thompson JF: Reconfirmation of clinical unpredictability of lymphatic drainage in cutaneous melanoma and new developments in sentinel lymph node diagnostics - Reply. *J NUCL MED* 44:1871-1872 (2003).
- Urosevic M, Dummer R: HLA-G in skin cancer: A wolf in sheep's clothing? *HUM IMMUNOL* 64:1073-1080 (2003).
- vandenAardweg GJM, Kiliç E, deKlein N, Luyten GPM: Dose fractionation effects in primary and metastatic human uveal melanoma cell lines. *INVEST OPHTHALMOL VISUAL SCI* 44:4660-4664 (2003).
- Veeramachaneni R, Turbat-Herrera EA: Cytomorphologic diagnosis of malignant melanoma by fine-needle aspiration. *J HISTOTECHNOL* 26:259-262 (2003).
- Velasco-Velázquez MA, Agramonte-Hevia J, Barrera D, Jiménez-Orozco A, García-Mondragón MJ, Mendoza-Patiño N, Landa A, Mandoki J: 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility. *CANCER LETT* 198:179-186 (2003).
- Velasco JM, Aranha GV, Agnese DM: Cost-effectiveness of sentinel lymph node biopsy in thin melanomas - Discussion. *SURGERY* 134:547-548 (2003).
- Vincent-Naulleau S, LeChalony C, Leplat JJ, Bouet S, Bailly C, Spatz A, Vielh P, Avril MF, Tricaud Y, Gruand J, Horak V, Frelat G, Geffrotin C: Clinical and histopathological characterization of cutaneous melanomas in the melanoblastoma-bearing Libechev minipig model. *PIGM CELL RES* 17:24-35 (2004).
- Wagner JD, Evdokimow DZ, Weisberger E, Moore D, Chuang TY, Wenck S, Coleman JJ: Sentinel node biopsy for high-risk nonmelanoma cutaneous malignancy. *ARCH DERMATOL* 140:75-79 (2004).

- Waldman A, Rees JH, Brock CS, Robson MD, Gatehouse PD, Bydder GM: MRI of the brain with ultra-short echo-time pulse sequences. *NEURORADIOLOGY* 45:887-892 (2003).
- Wang SQ, Kopf AW, Koenig K, Polsky D, Nudel K, Bart RS: Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. *J AMER ACAD DERMATOL* 50:15-20 (2004).
- Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. *GENE THERAPY* 10:2105-2111 (2003).
- Weber A, Henge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel MB, Wittekind C, Wiedemann P, Tannapfel A: Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. *LAB INVEST* 83:1771-1776 (2003).
- Weyandt GH, Eggert AO, Houf M, Raulf F, Bröcker EB, Becker JC: Anorectal melanoma: surgical management guidelines according to tumour thickness. *BRIT J CANCER* 89:2019-2022 (2003).
- Wick MR, Patterson JW: Multimodal pathologic diagnosis of malignant melanoma: Integration of morphology, histochemistry, immunohistology, and electron microscopy. *J HISTOTECHNOL* 26:253-258 (2003).
- Xia HC, Li F, Li Z, Zhang ZC: Purification and characterization of Moschatin, a novel type I ribosome-inactivating protein from the mature seeds of pumpkin (*Cucurbita moschata*), and preparation of its immunotoxin against human melanoma cells. *CELL RES* 13:369-374 (2003).
- Yang S, McNulty S, Meyskens FL: During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. *PIGM CELL RES* 17:74-83 (2004).
- Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL: Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? *ANN SURG* 238:743-747 (2003).
- Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rütten A, Mentzel T, Hügel H, Hantschke M, Schmid-Wendtner MH, Kutzner H, Sander CA: Mutations of the BRAF gene in benign and malignant melanocytic lesions. *J INVEST DERMATOL* 121:1160-1162 (2003).
- Yu GP, Hu DN, Finger PT: Conjunctival melanoma: Is it increasing in the United States? *AMER J OPHTHALMOL* 136:1190 (2003).
- Zámbó K, Koppán M, Paál A, Schmidt E, Tinneberg HR, Bódis J: Sentinel lymph nodes in gynaecological malignancies: frontline between TNM and clinical staging systems? *EUR J NUCL MED MOL IMAGING* 30:1684-1688 (2003).
- Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, Cavallo C, Uggeri J, Scandroglio R, Crafa P, Spagnoli GC, Ferrari C, Missale G: Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. *J HEPATOL* 40:102-109 (2004).
- Zhang H, Rosdahl I: Deletion in p16(INK4a) and loss of p16 expression in human skin primary and metastatic melanoma cells. *INT J ONCOL* 24:331-335 (2004).
- Zhang XM, Huang SP, Xu Q: Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. *CANCER CHEMOTHER PHARMACOL* 53:82-88 (2004).
- Zhang Y, Wu LJ, Tashiro S, Onodera S, Ikejima T: Intracellular regulation of evodiamine-induced A375-S2 cell death. *BIOL PHARM BULL* 26:1543-1547 (2003).
- Zhang Y, Wu LJ, Tashiro S, Onodera S, Ikejima T: Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis. *ACTA PHARMACOL SIN* 25:83-89 (2004).
- Zografos L, Ducrey N, Beati D, Schalenbourg A, Spahn B, Balmer A, Othenin-Girard CB, Chamot L, Egger E: Metastatic melanoma in the eye and orbit. *OPHTHALMOLOGY* 110:2245-2256 (2003).
- Zuberek K, Ling V, Wu P, Ma HL, Leonard JP, Collins M, Dunussi-Joannopoulos K: Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFN γ -dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. *CELL IMMUNOL* 225:53-63 (2003).
- Zuidervaart W, vanderVelden PA, Hurks MH, vanNieuwpoort FA, Out-Luiting CJJ, Singh AD, Frants RR, Jager MJ, Gruis NA: Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. *BRIT J CANCER* 89:1914-1919 (2003).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- Albert MR, Ostheimer KG: The evolution of current medical and popular attitudes toward ultraviolet light exposure: Part 3. *J AMER ACAD DERMATOL* 49:1096-1106 (2003).
- Chakraborty AK, Kolesnikova N, Sousa JD, Espreafico EM, Peronni KC, Pawelek J: Expression of c-Met proto-oncogene in metastatic macrophage x melanoma fusion hybrids: Implication of its possible role in MSH-induced motility. *ONCOL RES* 14:163-174 (2003).
- Hearle N, Humphreys J, Damato BE, Wort R, Talaban R, Wixey J, Green H, Easton DF, Houlston RS: Role of MC1R variants in uveal melanoma. *BRIT J CANCER* 89:1961-1965 (2003).
- Laurent V, Jaubert-Miazza L, Desjardins R, Day R, Lindberg I: Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice. *ENDOCRINOLOGY* 145:519-528 (2004).
- Miao YB, Whitener D, Feng WW, Owen NK, Cheng JQ, Quinn TP: Evaluation of the human melanoma targeting properties of radiolabeled $\alpha\delta$ -melanocyte stimulating hormone peptide analogues. *BIOCONJUGATE CHEMISTRY* 14:1177-1184 (2003).
- Milligan G: Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. *MOL PHARMACOL* 64:1271-1276 (2003).
- Shiratori K, Ohgami K, Ilieva IB, Koyama Y, Yoshida K, Ohno S: Inhibition of endotoxin-induced uveitis and potentiation of cyclooxygenase-2 protein expression by $\alpha\delta$ -melanocyte-stimulating hormone. *INVEST OPHTHALMOL VISUAL SCI* 45:159-164 (2004).
- Song Y, Golling G, Thacker TL, Cone RD: Agouti-related protein (AGRP) is conserved and regulated by metabolic state in the zebrafish, *Danio rerio*. *ENDOCRINE* 22:257-265 (2003).
- Tanaka S: Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: Studies of proopiomelanocortin processing. *ZOOL SCI* 20:1183-1198 (2003).
- Vagner J, Handl HL, Gillies RJ, Hruby VJ: Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of $\alpha\delta$ -MSH. *BIOORG MEDICINAL CHEM LETTER* 14:211-215 (2004).

DEVELOPMENTAL BIOLOGY

- Cresko WA, Yan YL, Baltrus DA, Amores A, Singer A, Rodríguez-Marí A, Postlethwait JH: Genome duplication, subfunction partitioning, and lineage divergence: *Sox9* in stickleback and zebrafish. *DEVELOP DYNAM* 228:480-489 (2003).
- Garcia-Barceló M, Sham MH, Lee WS, Lui VCH, Chen BLS, Wong KKY, Wong JSW, Tam PKH: Highly recurrent RET mutations and novel mutations in genes of the receptor tyrosine kinase and endothelin receptor B pathways in Chinese patients with sporadic Hirschsprung disease. *CLIN CHEM* 50:93-100 (2004).
- Hou L, Loftus SK, Incao A, Chen A, Pavan WJ: Complementation of melanocyte development in *SOX10* mutant neural crest using lineage-directed gene transfer. *DEVELOP DYNAM* 229:54-62 (2004).
- Kang JS, Lee CJ, Lee JM, Rha JY, Song KW, Park MH: Follicular expression of c-Kit/SCF and inhibin- $\alpha\delta$ in mouse ovary during development. *J HISTOCHEM CYTOCHEM* 51:1447-1458 (2003).
- Kruger GM, Mosher JT, Tsai TH, Yeager KJ, Iwashita T, Garipey CE, Morrison SJ: Temporally distinct requirements for endothelin receptor B in the generation and migration of gut neural crest stem cells. *NEURON* 40:917-929 (2003).
- MacDougall-Shackleton EA, Blanchard L, Gibbs HL: Unmelanized plumage patterns in old world leaf warblers do not correspond to sequence variation at the melanocortin-1 receptor locus (*MC1R*) (vol 20, pg 1675, 2003). *MOL BIOL EVOL* 20:1946 (2003).
- Rao C, Foernzler D, Loftus SK, Liu SM, McPherson JD, Jungers KA, Apte SS, Pavan WJ, Beier DR: A defect in a novel ADAMTS family member is the cause of the belted white-spotting mutation. *DEVELOPMENT* 130:4665-4672 (2003).
- Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schäfer BW, Buckingham M: The transcriptional activator *PAX3-FKHR* rescues the defects of *Pax3* mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. *GENE DEVELOP* 17:2950-2965 (2003).
- Rushlow C: Dorsoroventral patterning: A serpin pinned down at last. *CURR BIOL* 14:R16-R18 (2004).

DIFFERENTIATION

- Al Khenazian S: Hyperpigmentation in Chediak-Higashi syndrome. *J AMER ACAD DERMATOL* 49:S244-S246 (2003).
- Béjar J, Hong YH, Scharl M: Mitf expression is sufficient to direct differentiation of medaka blastula derived stem cells to melanocytes. *DEVELOPMENT* 130:6545-6553 (2003).
- Burdon KP, Wilkinson RM, Barbour JM, Dickinson JL, Stankovich JM, Mackey DA, Sale MM: Investigation of albinism genes in congenital esotropia. *MOL VIS* 9:710-714 (2003).
- Chen Q, Chen QX, Qiu L, Song KK, Huang H: Inhibitory effect of 4-cyanobenzaldehyde and 4-cyanobenzoic acid on mushroom (*Agaricus bisporus*) tyrosinase. *J PROTEIN CHEM* 22:607-612 (2003).
- Chen QX, Huang H, Kubo I: Inactivation kinetics of mushroom tyrosinase by cetylpyridinium chloride. *J PROTEIN CHEM* 22:481-487 (2003).
- Chen K, Minwalla L, Ni L, Orlow SJ: Correction of defective early tyrosinase processing by bafilomycin A1 and monensin in pink-eyed dilution melanocytes. *PIGM CELL RES* 17:36-42 (2004).
- Chen QX, Song KK, Wang Q, Huang H: Inhibitory effects on mushroom tyrosinase by some alkylbenzaldehydes. *J ENZYM INHIB MED CHEM* 18:491-496 (2003).
- Cronin CA, Ryan AB, Talley EM, Scrabble H: Tyrosinase expression during neuroblast divisions affects later pathfinding by retinal ganglion cells. *J NEUROSCI* 23:11692-11697 (2003).
- Fenoll LG, García-Ruiz PA, Varón R, García-Cánovas F: Kinetic study of the oxidation of quercetin by mushroom tyrosinase. *J AGR FOOD CHEM* 51:7781-7787 (2003).
- Fenoll LG, Peñalver MJ, Rodríguez-López JN, Varón R, García-Cánovas F, Tudela J: Tyrosinase kinetics: discrimination between two models to explain the oxidation mechanism of monophenol and diphenol substrates. *INT J BIOCHEM CELL BIOL* 36:235-246 (2004).
- Fryer JP, Oetting WS, King RA: Identification and characterization of a DNase hypersensitive region of the human tyrosinase gene. *PIGM CELL RES* 16:679-684 (2003).
- Gandía-Herrero F, Jiménez M, Cabanes J, García-Carmona F, Escribano J: Tyrosinase inhibitory activity of cucumber compounds: Enzymes responsible for browning in cucumber. *J AGR FOOD CHEM* 51:7764-7769 (2003).
- Giménez E, Lavado A, Giraldo P, Montoliu L: Tyrosinase gene expression is not detected in mouse brain outside the retinal pigment epithelium cells. *EUR J NEUROSCI* 18:2673-2676 (2003).
- Giraldo P, Martínez A, Regales L, Lavado A, García-Díaz A, Alonso A, Busturia A, Montoliu L: Functional dissection of the mouse tyrosinase locus control region identifies a new putative boundary activity. *NUCL ACID RES* 31:6290-6305 (2003).
- Ho PY, Chiou MS, Chao AC: Production of L-DOPA by tyrosinase immobilized on modified polystyrene. *APPL BIOCHEM BIOTECH* 111:139-152 (2003).
- Huber WE, Price ER, Widlund HR, Du JY, Davis IJ, Wegner M, Fisher DE: A tissue-restricted cAMP transcriptional response - SOX10 modulates α -melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. *J BIOL CHEM* 278:45224-45230 (2003).
- Jiang H, Shi CH, Xie YS, Xu XL, Liu QL: Activation of tobacco leaf polyphenol oxidase by sodium dodecyl sulfate. *INDIAN J BIOCHEM BIOPHYS* 40:350-353 (2003).
- Kim SM, Han S: Tyrosinase scavenges tyrosyl radical. *BIOCHEM BIOPHYS RES COMMUN* 312:642-649 (2003).
- Levy C, Sonnenblick A, Razin E: Role played by microphthalmia transcription factor phosphorylation and its zip domain in its transcriptional inhibition by PIAS3. *MOL CELL BIOL* 23:9073-9080 (2003).
- Lotz C, Ferreira EA, Drexler I, Mutallib SA, Huber C, Suter G, Theobald M: Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. *INT J CANCER* 108:571-579 (2004).
- Ludwig A, Rehberg S, Wegner M: Melanocyte-specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factors. *FEBS LETT* 556:236-244 (2004).
- Miyazawa M, Oshima T, Koshio K, Itsuzaki Y, Anzai J: Tyrosinase inhibitor from black rice bran. *J AGR FOOD CHEM* 51:6953-6956 (2003).

- Mohideen MAPK, Beckwith LG, Tsao-Wu GS, Moore JL, Wong ACC, Chinoy MR, Cheng KC: Histology-based screen for zebrafish mutants with abnormal cell differentiation. *DEVELOP DYNAM* 228:414-423 (2003).
- Park YD, Jung JY, Kim DW, Kim WS, Hahn MJ, Yang JM: Kinetic inactivation study of mushroom tyrosinase: Intermediate detection by denaturants. *J PROTEIN CHEM* 22:463-471 (2003).
- Park YD, Lee SJ, Park KH, Kim SY, Hahn MJ, Yang JM: Effect of thiohydroxyl compounds on tyrosinase: Inactivation and reactivation study. *J PROTEIN CHEM* 22:613-623 (2003).
- Park YD, Lee JR, Park KH, Hahn HS, Hahn MJ, Yang JM: A new continuous spectrophotometric assay method for DOPA oxidase activity of tyrosinase. *J PROTEIN CHEM* 22:473-480 (2003).
- Regales L, Giraldo P, García-Díaz A, Lavado A, Montoliu L: Identification and functional validation of a 5' upstream regulatory sequence in the human tyrosinase gene homologous to the locus control region of the mouse tyrosinase gene. *PIGM CELL RES* 16:685-692 (2003).
- Schmutz SM, Berryere TG, Ciobanu DC, Mileham AJ, Schmitz BH, Fredholm M: A form of albinism in cattle is caused by a tyrosinase frameshift mutation. *MAMM GENOME* 15:62-67 (2004).
- Sen I, Thapa D, Gombar KK: Oculocutaneous albinism and spurious pulse oximetry. *ANESTH ANALG* 98:553 (2004).
- Tolmachova T, Anders R, Stinchombe J, Bossi G, Griffiths GM, Huxley C, Seabra MC: A general role for Rab27a in secretory cells. *MOL BIOL CELL* 15:332-344 (2004).
- Tonks ID, Nurcombe V, Paterson C, Zournazi A, Prather C, Mould AW, Kay GF: Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. *GENESIS* 37:131-138 (2003).
- Um SJ, Park MS, Park SH, Han HS, Kwon YJ, Sin HS: Synthesis of new glycyrrhetic acid (GA) derivatives and their effects on tyrosinase activity. *BIOORGAN MED CHEM* 11:5345-5352 (2003).
- Vachtenheim J, Drdová B: A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative. *PIGM CELL RES* 17:43-50 (2004).
- Wu H, Park HY: Protein kinase C- $\beta\delta$ -mediated complex formation between tyrosinase and TRP-1. *BIOCHEM BIOPHYS RES COMMUN* 311:948-953 (2003).
- Yajima L, Endo K, Sato S, Toyoda R, Wada H, Shibahara S, Numakunai T, Ikeo K, Gojobori T, Goding CR, Yamamoto H: Cloning and functional analysis of ascidian Mitf in vivo: insights into the origin of vertebrate pigment cells. *MECH DEVELOP* 120:1489-1504 (2003).

MISCELLANEOUS

- Majerus MEN, Mundy NI: Mammalian melanism: natural selection in black and white. *TRENDS GENET* 19:585-588 (2003).
- Taylor SRD: "SunSmart Plus": the more informed use of sunscreens. *MED J AUSTRALIA* 180:36-37 (2004).
- VanderSalm AL, Pavlidis M, Flik G, Bonga SEW: Differential release of $\alpha\delta$ -melanophore stimulating hormone isoforms by the pituitary gland of red porgy, *Pagrus pagrus*. *GEN COMP ENDOCRINOL* 135:126-133 (2004).
- Young AR: Tanning devices - Fast track to skin cancer? *PIGM CELL RES* 17:2-9 (2004).

PASPCR Membership list

This is a membership listing for the PASPCR, 2004. If there is an asterisk after your name, please check with Ray Boissy to make sure that your annual dues for the PASPCR are paid up.

Abdel-Malek, Zalfa A. Ph.D.
University of Cincinnati
Department of Dermatology
P.O. Box 670592
Cincinnati, OH 45267-0592 U.S.A.
Phone: (513) 558-6242
FAX: (513) 558-0198
E-mail: abdelmza@email.uc.edu

Aplin, Andrew E. Ph.D.
Albany Medical College
Department of Cell Biology & Cancer Research
47 New Scotland Avenue
Albany, NY 12208 U.S.A.
Phone: 518-262-5700
FAX: 518-262-5669
E-mail: aplina@mail.amc.edu

Bagnara, Joseph T. Ph.D.
University of Arizona
Department of Cell Biology and Anatomy
1501 N. Campbell
Tucson, AZ 85724 U.S.A.
Phone: (520) 621-7516
FAX: (520) 621-9339
E-mail: bagnara@u.arizona.edu

Balin, Arthur K. M.D., Ph.D. *
110 Chesley Drive
Media, PA 19063 U.S.A.
Phone: 610-565-9909
E-mail: akbalin@aol.com

Barsh Gregory, MD, PhD *
Howard Hughes Medical Institute
Stanford University School of Medicine
Beckman Center, B271
Stanford, CA 94305-5428
Phone: (415) 723-5061
FAX: (415) 723-1399
Email: gbarsh@cmgm.stanford.edu

Bennett, Dorothy C. M.A., Ph.D. *
St. George's Hospital Medical School
Division of Anatomy & Developmental Biology
Cranmer Terrace
London, SW17 0RE UNITED KINGDOM
Phone: 44-20-8725-5202
FAX: 44-20-8725-3326
E-mail: dbennett@sghms.ac.uk

Bhawan, Jag M.D.
Boston University School of Medicine
Department of Dermatology
609 Albany Street, Room 309
Boston, MA 02118 U.S.A.
Phone: (617) 638-5570
FAX: (617) 638-5575
E-mail: jbhawan@bu.edu

Bissett, Donald L. Ph.D.
Procter & Gamble
Skin Care
PO Box 538707
Cincinnati, OH 45253-8707 U.S.A.
Phone: 513-627-2471
FAX: 513-627-0575
E-mail: bissett.dl@pg.com

Boissy, Raymond E. Ph.D.
University of Cincinnati
Department of Dermatology
P.O. Box 670592
Cincinnati, OH 45267-0592 U.S.A.
Phone: (513) 558-6242
FAX: (513) 558-0198
E-mail: boissyre@ucmail.uc.edu

Bologna, Jean L. M.D.
Yale Medical School
Department of Dermatology
333 Cedar Street
New Haven, CT 06510 U.S.A.
Phone: (203) 785-4092
FAX: (203) 785-7637
E-mail: jean.bologna@yale.edu

Bonte, Frederic Ph.D.
LVMH R and D
Av de Verdun
St. Jean De Braye, 45804 France
Phone: 33-0238-60-3388
FAX: 33-0238-60-31-17
E-mail: fredericbonte@diormail.com

Bosko, Carol Ph.D.
Unilever Research
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2575
FAX: 201-840-8291
E-mail: carol.bosko@unilever.com

Bowers, Roger R. Ph.D.
California State University, Los Angeles
Department of Biology
5151 State University Drive
Biological Sciences Building 333
Los Angeles, CA 90032 U.S.A.
Phone: (323) 343-2081
FAX: (323) 343-6451
E-mail: rbowers@calstatela.edu

Brilliant, Murray H. Ph.D.

University of Arizona
Department of Pediatrics
P.O. Box 245073
1501 N. Campbell
Tucson, AZ 85724 U.S.A.
Phone: (520) 626-3305
FAX: (520) 626-7407
E-mail: mhb@peds.arizona.edu

Brissette, Janice L. Ph.D.

Massachusetts General Hospital, Harvard Medical School
Cutaneous Biology Research Center, Department of
Dermatology
MGH-East, Building 149 - 3rd Floor
13th Street
Charlestown, MA 02129 U.S.A.
Phone: 617-726-4438
FAX: 617-726-4453
E-mail: janice.brissette@cbr2.mgh.harvard.edu

Brown, David A. Ph.D. *

AGI Dermatics
Department of Research
205 Buffalo Avenue
Freeport, NY 11520 U.S.A.
Phone: 516-868-9026
FAX: 516-868-9143
E-mail: dabrown@agiderm.com

Burnett, Jean B. Ph.D.

P.O. Box 805
Okemos, MI 48805-0805 U.S.A.
Phone: 989-539-2820

Chen, Suzie Ph.D.

Rutgers University
Department of Chemical Biology
164 Frelinghuysen Road
Piscataway, NJ 08854 U.S.A.
Phone: 732-445-3400 (x227)
FAX: 732-445-0687
E-mail: suziec@rci.rutgers.edu

Christiansen, James L. Ph.D.

Drake University
Department of Biology
25th and University Avenue
Des Moines, IA 50311 U.S.A.
Phone: (515) 271-2821
FAX: (515) 271-3702
E-mail: james.christiansen@drake.edu

Cohen-Solal, Karine A. Ph.D. *

Rutgers University
Department of Chemical Biology
164 Frelinghuysen Road
Piscataway, NJ 08854 U.S.A.
Phone: 732-445-3400 (x228)
FAX: 732-445-0687
E-mail: karineco@rci.rutgers.edu

Costin, Gertrude-Emilia Ph.D.

National Cancer Inst / National Inst of Health
Laboratory of Cell Biology / Pigment Cell Research Section
37 Convent Drive, Building 37, Room 1C20
Bethesda, MD 20892-4254 U.S.A.
Phone: 301-435-4684
FAX: 301-435-8188
E-mail: costing@mail.nih.gov

Cullen, Mary K. M.D.

6315 Pershing
St. Louis, MO 63130 U.S.A.
Phone: (314) 721-8267
E-mail: mkcullen@earthlink.net

Dell'Angelica, Esteban C Ph.D.

University of California, Los Angeles
Department of Human Genetics
Gonda Center, Room 6357B
Los Angeles, CA 90095-7088 U.S.A.
Phone: 310-206-3749
FAX: 310-794-5446
E-mail: edellangelica@mednet.ucla.edu

Erf, Gisela F. Ph.D.

University of Arkansas
Department of Poultry Science
Poultry Science Center
Fayetteville, AR 72701 U.S.A.
Phone: 479-575-8664
FAX: 479-575-7139
E-mail: gferf@uark.edu

Eun, Aea Kyung M.D.

34-306, Han Gang Mansion Apt.,
300-68, Ichon-1-Dong, Yongsan-Gu
Seoul, 140-724 SOUTH KOREA
Phone: 8211-9191-1225
E-mail: yellow46@unitel.co.kr

Fang, Dong Ph.D.

The Wistar Institute
Program of Tumor Biology, Room 489
3601 Spruce Street
Philadelphia, PA 19104 U.S.A.
Phone: 215-898-0032
FAX: 215-898-0980
E-mail: fang@wistar.upenn.edu

Faraco, Cloris D. Ph.D.

Universidade Federal Do Parana
Biologia Celular
Av. Nossa Senhora da Luz, 250
Curitiba Parana, 82510-020 BRAZIL
Phone: 41-357-1298
FAX: 41-256-7575
E-mail: cloris.faraco@brtvrbo.br

Farmer, Patrick J. Ph.D. *
University of California, Irvine
Department of Chemistry
Natural Sciences I
Irvine, CA 92697-2025 U.S.A.
Phone: 949-824-6079
FAX: 949-824-9920
E-mail: pfarmer@uci.edu

Fernandez, Philip J. Ph.D.
Grand Canyon University
Department of Biology
3300 W. Camelback Road
Phoenix, AZ 85017 U.S.A.
Phone: (602) 589-2575
FAX: (602) 589-2716
E-mail: pfernandez@grand-canyon.edu

Froiland, Thomas G. Ph.D. *
Northern Michigan University
Department of Biology
2107 New Science
1401 Presque Isle Avenue
Marquette, MI 49855 U.S.A.
Phone: (906) 227-2310
FAX: (906) 227-1063
E-mail: tfroilan@nmu.edu

Frost Mason, Sally K. Ph.D.
Purdue University
Office of the Provost
610 Purdue Mall, Room 100
West Lafayette, IN 47907-1073 U.S.A.
Phone: 765-494-9709
E-mail: sfmason@purdue.edu

Fuller, Bryan B. Ph.D.
OUHSC
Research Park Building
800 North Research Parkway, Suite #400
Oklahoma City, OK 73104-3698 U.S.A.
Phone: (405) 271-2160
FAX: (405) 271-7184
E-mail: bryan-fuller@ouhsc.edu

Grichnik, James M. M.D., Ph.D.
Duke University Medical Center
Department of Medicine, Division of Dermatology
Box 3135
Durham, NC 27710 U.S.A.
Phone: 919-684-3270
FAX: 919-684-3002
E-mail: grich001@mc.duke.edu

Grimes, Pearl E. M.D.
321 N. Larchmont Blvd., Suite 617
Los Angeles, CA 90004 U.S.A.
Phone: (323) 467-4398
FAX: (323) 467-4488
E-mail: pegrimesmd@earthlink.net

Gunn, Teresa M. Ph.D.
Cornell University
Department of Biomedical Sciences
T2006B VRT
Ithaca, NY 14853 U.S.A.
Phone: 607-253-4359
FAX: 607-253-4212
E-mail: tmg25@cornell.edu

Halaban, Ruth Ph.D. *
Yale Medical School
Department of Dermatology
P.O. Box 208059
15 York Street
New Haven, CT 06520-8059 U.S.A.
Phone: (203) 785-4352
FAX: (203) 785-7234
E-mail: ruth.halaban@yale.edu

Hazneci, Ersoy M.D.
Turgut Ozal Tip Merkezi
Malatya, 44315 Turkiye\TURKEY
Phone: 0-90-422-3411178
E-mail: ehazneci@inonu.edu.tr

Hearing, Elizabeth D.
43635 Hopkins Mill Terrace
Leesburg, VA 20176 U.S.A.
E-mail: hearing@dass-ms.com

Hearing, Vincent J. Ph.D.
NCI, National Institutes of Health
Laboratory of Cell Biology
Building 37, Room 1B25
9000 Rockville Pike
Bethesda, MD 20892 U.S.A.
Phone: (301) 496-1564
FAX: (301) 402-8787
E-mail: hearingv@nih.gov

Herlyn, Meenhard D.V.M.
The Wistar Institute
Program of Molecular and Cellular Oncogenesis
3601 Spruce Street
Philadelphia, PA 19104-4268 U.S.A.
Phone: (215) 898-3950
FAX: (215) 898-0980
E-mail: herlynm@wistar.upenn.edu

Hill, Helene Z. Ph.D.
New Jersey Medical School
Department of Radiology
185 South Orange Avenue, MSB F452
Newark, NJ 07103-2714 U.S.A.
Phone: (973) 972-3421
FAX: (973) 972-5592
E-mail: hill@umdnj.edu

Hixon, Ernest R. B.S.
University of Maryland
Department of Biology
Building 144, Room 2257
College Park, MD 20742 U.S.A.
Phone: 301-475-7577
FAX: 301-314-9358
E-mail: eh127@umail.umd.edu

Hoffman, Robert M. Ph.D.
AntiCancer, Inc.
7917 Ostrow Street
San Diego, CA 92111 U.S.A.
Phone: (858) 654-2555
FAX: (858) 268-4175
E-mail: all@anticancer.com

Hornyak, Thomas J. M.D., Ph.D.
Center for Cancer Research / NCI / NIH
Dermatology Branch
10 Center Drive, Building 10, room 12N242
Bethesda, MD 20892 U.S.A.
Phone: 301-451-1926
FAX: 301-496-5370
E-mail: hornyakt@mail.nih.gov

Hou, Ling Ph.D.
National Human Genome Research Institute, National Inst.
Of Health
Genetic Disease Research Branch
Building 49, Room 4C80
49 Convent Drive, MSC4472
Bethesda, MD 20892 U.S.A.
Phone: 301-402-2036
FAX: 301-402-2170
E-mail: lhou@nhgri.nih.gov

Houghton, Alan N. M.D. *
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10021 U.S.A.
Phone: (212) 639-7595
FAX: (212) 794-4352
E-mail: a-houghton@ski.mskcc.org

Huizing, Marjan Ph.D.
National Institutes of Health
NHGRI
10 Center Drive, Bldg. 10, Rm 10C-103
Bethesda, MD 20892-1851 U.S.A.
Phone: 301-402-2797
FAX: 301-496-7184
E-mail: mhuizing@mail.nih.gov

Ito, Shosuke Ph.D.
Fujita Health University
School of Health Sciences
Toyoake, Aichi 470-1192 Japan
Phone: 81-562-93-2595
FAX: 81-562-93-4595
E-mail: sito@fujita-hu.ac.jp

Ittah, Avner *
Florida International University
Department of Biological Sciences
Park Campus
Miami, FL 33199 U.S.A.
Phone: 305-348-6164
FAX: 305-348-1986
E-mail: aittah01@fiu.edu

Jamal, Sumayah M.D., Ph.D.
New York University Medical Center
Department of Biochemistry
550 First Avenue
New York, NY 10016 U.S.A.
Phone: (212) 263-6007
FAX: (212) 263-8276
E-mail: jamals01@mcrcr0.med.nyu.edu

Kadekaro, Ana Luisa Ph.D.
University of Cincinnati
Department of Dermatology
231 Albert Sabin Way, Room 7409
PO Box 670592
Cincinnati, OH 45267-0592 U.S.A.
Phone: 513-558-6242
FAX: 513-558-0198
E-mail: kadekaro@hotmail.com

Kameyama, Koichiro
Aoyama Dermatologic Clinic
5-1-3 Mimaniaoyama 8F
Minato
Tokyo, 107-0062 JAPAN
Phone: 81-3-3499-1214
FAX: 81-3-3499-1281
E-mail: dr@aoyamahihuka.com

Kempf, Valerie R. B.S.
Duke University
Department of Chemistry
P.M. Gross Chemical Laboratory
Durham, NC 27708 U.S.A.
Phone: 919-660-1630
FAX: 919-660-1605
E-mail: valerie.kempf@duke.edu

King, Richard A. M.D., Ph.D.
University of Minnesota
MMC 485 Mayo
420 Delaware Street, S.E.
Minneapolis, MN 55455 U.S.A.
Phone: (612) 624-6657
FAX: (612) 624-6645
E-mail: kingx002@umn.edu

Kobayashi, Nobuhiko M.D., Ph.D.
Nara Medical University
Department of Dermatology
Kashihara
Nara, 634-8522 JAPAN
Phone: 81-744-29-8891
FAX: 81-744-25-8511
E-mail: nobuk@naramed-u.ac.jp

Kos, Lidia Ph.D.
Florida International University
Department of Biological Sciences
University Park Campus
Miami, FL 33199 U.S.A.
Phone: 305-348-6678
FAX: 305-348-1986
E-mail: kosl@fiu.edu

Kramer, Gregory J. *
The Procter & Gamble Company
PO Box 538707
Cincinnati, OH 45253 U.S.A.
Phone: (513) 627-1310
FAX: (513) 627-0139
E-mail: kramer.gj@pg.com

Krauss, Achim H. Ph.D.
Allergan, Inc.
Department of Biological Sciences
2525 Dupont Drive
Irvine, CA 92612 U.S.A.
Phone: 714-246-4842
FAX: 714-246-5578
E-mail: krauss_achim@allergan.com

Kuliawat, Regina M. Ph.D.
Albert Einstein College of Medicine
Department of Medicine, Division of Endocrinology
1300 Morris Park Avenue
Bronx, NY 10461 U.S.A.
Phone: 718-430-8686
FAX: 718-430-8557
E-mail: kuliawat@aecom.yu.edu

Lamoreux, M. Lynn, PhD
Texas A & M University
Department of Veterinary Pathobiology
College Station, TX 77843
Phone: (409) 845-6084
FAX: (409) 845-9972
Email: llamoreux@cvm.tamu.edu

Le Poole, I. Caroline Ph.D.
Loyola University Medical Center
Department of Pathology
Cancer Center, Bldg. 112, Room 203
2160 South First Avenue
Maywood, IL 60153 U.S.A.
Phone: (708) 327-2032
FAX: (708) 327-3238
E-mail: ilepool@lumc.edu

Leachman, Sancy A. M.D., Ph.D.
University of Utah, Huntsman Cancer Institute
Department of Dermatology
2000 Circle of Hope, Suite 5242
Salt Lake City, UT 84112 U.S.A.
Phone: 801-585-1810
FAX: 801-585-7477
E-mail: sancy.leachman@hci.utah.edu

Lee, Eun So
Jongno Officetel 318 Room
Suite 58-01, RackWon-Dong, Jongno-Gu
Seoul, 110320 SOUTH KOREA
E-mail: tamarind@unitel.co.kr

Lee, Mu-Hyoung M.D., Ph.D.
Kyunghee University Hospital
Department of Dermatology
1, Hoeki-Dong, Dongdaemun-Ku
Seoul, 130-702 SOUTH KOREA
Phone: 82-2-958-8512
FAX: 82-2-969-6538
E-mail: mhlee@khmc.or.kr

Lei, Tie Chi M.D., Ph.D. *
5113 Crossfield Ct., Apt. 4
Rockville, MD 20852 U.S.A.
Phone: 301-738-0408
FAX: 301-517-0344
E-mail: tiechilei@yahoo.com

Lerner, Aaron B. M.D., Ph.D.
34 Old Mill Road
Woodbridge, CT 06525 U.S.A.
Phone: 203-397-3946
FAX: 203-397-3944
E-mail: aaron.lerner@yale.edu

Lin, Connie B. Ph.D.
Skin Research Center
199 Grandview Road
Skillman, NJ 08558 U.S.A.
Phone: 908-874-1532
FAX: 908-874-2323
E-mail: blin1@cpcus.jnj.com

Lister, James A. Ph.D.
University of Washington
Department of Biological Structure
Box 357420
Seattle, WA 98195-7420 U.S.A.
Phone: 206-616-7467
FAX: 206-543-1524
E-mail: jalister@u.washington.edu

Liu, Yan Ph.D.
Duke University
Department of Chemistry
P.M. Gross Chemical Laboratory
P.O. Box 90346
Durham, NC 27708 U.S.A.
Phone: 919-660-1630
FAX: 919-660-1605
E-mail: yanliu@chem.duke.edu

Manga, Prashiela Ph.D.
University of Cincinnati
Department of Dermatology
231 Albert Sabin Way
PO Box 670592
Cincinnati, OH 45267-0592 U.S.A.
Phone: 513-558-6242
FAX: 513-558-0198
E-mail: mangap@email.uc.edu

Marin, Yari E. *
Rutgers University
Department of Chemical Biology
164 Frelinghyusen Road
Piscataway, NJ 08854 U.S.A.
Phone: 732-445-3400, ext. 225
FAX: 732-445-0687
E-mail: yarimarin@hotmail.com

Matsumoto, Katsuo B.S.
POLA Laboratories
560 Kashio-Cho, Tozuka-Ku
Yokohama, 244 0812 Japan
Phone: 81-45-826-7231
FAX: 81-45-826-7249
E-mail: katsuom@pola.co.jp

Matsunaga, Naoko M.D. *
2-15-2-101 Tsunogoro
Aoba-ku, Sendai
Miyagi, 980-0874 JAPAN
Phone: 81-22-263-8258
FAX: 81-22-263-8258
E-mail: NQA27403@nitty.com

McCormack, Wayne T. Ph.D.
University of Florida College of Medicine
Dept of Pathology, Immunology & Lab Med
1600 S.W. Archer Road
Box 100275
Gainesville, FL 32610-0275 U.S.A.
Phone: 352-392-3053
FAX: 352-846-3466
E-mail: mccormac@pathology.ufl.edu

McNulty, Susan E. Ph.D.
University of California, Irvine
Department of Medicine
Room 436, Building 23, Rt. 81
101 City Drive South
Orange, CA 92868 U.S.A.
Phone: 714-456-2923
FAX: 714-456-2240
E-mail: smcnulty@uci.edu

Meadows, Gary G. Ph.D.
Washington State University
College of Pharmacy, Cancer Prevention and Research
Center
Box 646510
334 Wegner Hall on Stadium Way
Pullman, WA 99164-6510 U.S.A.
Phone: 509-335-4753
FAX: 509-335-7559
E-mail: meadows@wsu.edu

Medrano, Estela E. Ph.D.
Baylor College of Medicine
Huffington Center on Aging
Department of Molecular and Cellular Biology
One Baylor Plaza, M-320
Houston, TX 77054 U.S.A.
Phone: 713-798-1569
FAX: 713-798-4161
E-mail: medrano@bcm.tmc.edu

Meyskens, Frank L. Jr., M.D.
University of California
Comprehensive Cancer Center
101 City Drive, Building 230
Orange, CA 92868 U.S.A.
Phone: (714) 456-6310
FAX: (714) 456-2240
E-mail: flmeyske@uci.edu

Mintz, Beatrice Ph.D.
Institute for Cancer Research
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111 U.S.A.
Phone: (215) 728-2479
FAX: (215) 728-3574

Morrison, Randall L. Ph.D.
McDaniel College
Department of Biology
2 College Hill
Westminster, MD 21157 U.S.A.
Phone: (410) 857-2409
FAX: (410) 386-4613
E-mail: rmorriso@mcdaniel.edu

Namkoong, Jin
Rutgers University
Department of Chemical Biology
164 Frelinghuysen Road, Room 204
Piscataway, NJ 08854 U.S.A.
Phone: 732-445-3400, ext. 240
FAX: 732-445-0687
E-mail: jinnk1999@hotmail.com

Naughten, John C. Ph.D.
Northern State University
Department of Biology
1200 S. Jay Street
Aberdeen, SD 57401 U.S.A.
Phone: 605-626-2456
FAX: 605-626-3364
E-mail: naughtej@northern.edu

Niles, Richard Ph.D.
Marshall University School of Medicine
Dept of Biochemistry and Molecular Biology
1542 Spring Valley Drive
Huntington, WV 25704 U.S.A.
Phone: 304-696-7322
FAX: 304-696-7253

Nip, John Ph.D. *
Unilever Research U.S.
Department of Skin Bioscience
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2517
FAX: 201-840-8291
E-mail: john.nip@unilever.com

Noonan, Frances P. Ph.D.
George Washington University Medical Center
Dept of Environmental & Occupational Health
School of Public Health & Health Services
2300 Eye Street, N.W., Ross Hall, Room 113
Washington, DC 20037 U.S.A.
Phone: 202-994-3970
FAX: 202-994-0409
E-mail: drmfpn@gwumc.edu

Nordlund, James J. M.D.
3519 Principio
Cincinnati, OH 45208 U.S.A.
Phone: (513) 871-4168
FAX: (513) 871-6214
E-mail: jjnordlund@fuse.net

Norton, Heather L. M.A.
Pennsylvania State University
Department of Anthropology
409 Carpenter Building
University Park, PA 16802 U.S.A.
Phone: 814-863-7740
FAX: 814-863-1474
E-mail: hln109@psu.edu

Oetting, William S. Ph.D.
University of Minnesota
Department of Medicine - Genetics
MMC 485
420 Delaware Street S.E.
Minneapolis, MN 55455 U.S.A.
Phone: (612) 624-1139
FAX: (612) 624-6645
E-mail: bill@lenti.med.umn.edu

Olshavsky, Michael A. Ph.D. *
The Procter and Gamble Company
Beauty Care Technology
11810 East Miami River Road
Ross, OH 45061 U.S.A.
Phone: 513-627-0099
FAX: 513-627-0170
E-mail: olshavsky.ma@pg.com

Orlow, Seth J. M.D., Ph.D.
New York University Medical Center
Department of Dermatology
560 First Avenue, Room H-100
New York, NY 10016 U.S.A.
Phone: (212) 263-5070
FAX: (212) 263-5819
E-mail: seth.orlow@med.nyu.edu

Park, Hee-Young Ph.D.
Boston University School of Medicine
Department of Dermatology
609 Albany Street, J-205
Boston, MA 02118 U.S.A.
Phone: (617) 638-5500
FAX: (617) 638-5515
E-mail: hypark@acs.bu.edu

Park, Kyoung C. M.D., Ph.D.
Seoul National University
College of Medicine
300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do
Seoul, 463-707 South Korea
Phone: 82-31-787-7311
FAX: 82-031-787-4058
E-mail: gcpark@snu.ac.kr

Pavan, William J. Ph.D.
National Institutes of Health
National Center for Human Genome Research
Building 49, Room 4A82
9000 Rockville Pike
Bethesda, MD 20892-4472 U.S.A.
Phone: (301) 496-7584
FAX: (301) 402-2170
E-mail: bpavan@nhgri.nih.gov

Pawelek, John M. Ph.D.
Yale Medical School
Department of Dermatology
333 Cedar Street
New Haven, CT 06510 U.S.A.
Phone: (203) 785-4411
FAX: (203) 785-7637
E-mail: john.pawelek@yale.edu

Pomerantz, Seymour H. Ph.D.
59 Sereni Street, Apt. 8
Rehovot, 76240 ISRAEL
Phone: 011-972-8-931-6541
FAX: 011-972-8-931-6541
E-mail: spomerantz@bezeqint.net

Potterf, S. Brian Ph.D.
Unilever Research, U.S.
Clinical Research and Biochemistry
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2135
FAX: 201-840-8289
E-mail: brian.potterf@unilever.com

Pratt, Michael J.
Agouron / Pfizer
10777 Science Center Drive
San Diego, CA 92121 U.S.A.

Qu, Di Ph.D.
Access Business Group
Research and Development, 50-1B
7575 Fulton Street East
Ada, MI 49355-0001 U.S.A.
Phone: 616-787-4403
FAX: 616-787-4445
E-mail: di_qu@accessbusinessgroup.com

Quevedo, Walter C. Ph.D.
Brown University
Division of Biology & Medicine
Box G-B599
Providence, RI 02912 U.S.A.
Phone: (401) 863-2758
FAX: (401) 863-1971
E-mail: walter_quevedo_jr@brown.edu

Rhodes, Arthur R. M.D., M.P.H.
Rush-Presbyterian-St. Luke's Medical Center
Department of Dermatology
1653 Congress Parkway, Kidston 507
Chicago, IL 60612 U.S.A.
Phone: (312) 942-6096
FAX: (312) 942-7778
E-mail: arthur_rhodes@rush.edu

Richmond, Bonnie L. Ph.D. *
543 Grandview Road
Alexandria, KY 41001 U.S.A.
Phone: 859-635-7456

Rocha, Sheila *
Unilever Research
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2756
FAX: 201-840-8291
E-mail: sheila.rocha@unilever.com

Rouzaud, Francois Ph.D.
National Cancer Institute, National Institutes of Health
Laboratory of Cell Biology
Building 37, Room 1C20
Bethesda, MD 20892 U.S.A.
Phone: 301-435-6298
FAX: 301-435-8188
E-mail: rouzaudf@mail.nih.gov

Rupani, Reena N. *
111 Park Street, Apt. 5G
New Haven, CT 06511 U.S.A.
Phone: 203-777-9948
E-mail: reena.rupani@yale.edu

Samokhvalov, Alexander A. M.Sc. *
Duke University
Department of Chemistry
PM Gross Chemistry Building
Box 90349
Durham, NC 27708 U.S.A.
Phone: 919-660-1630
FAX: 919-660-1605
E-mail: samohval@duke.edu

Sampson, Ruth
238 Greenfield Avenue
San Mateo, CA 94403 U.S.A.
Phone: 650-572-2575
FAX: 650-341-4102
E-mail: ruths@rahul.net

Sangjin, Kang Ph.D.
LG Household & Healthcare Research Park
Biomaterials Development
84, Jang-Dong, Yusong
Daejeon, 305-343 KOREA
Phone: 82-42-860-8720
FAX: 82-42-863-2076
E-mail: sjkang@lgcare.co.kr

Santana, Isabel *
Unilever Research
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2218
FAX: 201-840-8291
E-mail: isabel.santana@unilever.com

Sasaki, Minoru
Kanebo, Ltd.
Basic Research Laboratory
5-3-28, Kotobuki-cho
Odawara, Kanagawa 250-0002 JAPAN
Phone: 81-465-34-6116
FAX: 81-465-34-3037
E-mail: msasaki@oda.cos.kanebo.co.jp

Schmutz, Sheila M. Ph.D.
University of Saskatchewan
Department of Animal Science
51 Campus Drive
Saskatoon, SK S7N 5A8 CANADA
Phone: 306-966-4153
FAX: 306-966-4151
E-mail: schmutz@sask.usask.ca

Scott, Glynis A. M.D.
University of Rochester School of Medicine
Department of Dermatology
601 Elmwood Avenue, Box 697
Rochester, NY 14642 U.S.A.
Phone: 585-275-3871
FAX: 585-273-1346
E-mail: Glynis_Scott@urmc.rochester.edu

Scott, Ian R. Ph.D. *
Unilever Research U.S.
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: (201) 840-2919

Seiberg, Miri Ph.D.
J & J CPWW
Skin Research Center
199 Grandview Road
Skillman, NJ 08558 U.S.A.
Phone: (908) 874-2325
FAX: (908) 874-2323
E-mail: mseiber@cpus.jnj.com

Setaluri, Vijayaradhi Ph.D.
Wake Forest University School of Medicine
Department of Dermatology
Winston-Salem, NC 27157 U.S.A.
Phone: (336) 716-3273
FAX: (336) 716-7732
E-mail: setaluri@wfubmc.edu

Shin, Myung K. Ph.D.
Fox Chase Cancer Center
Cellular and Developmental Biology Program
7701 Burholme Avenue
Philadelphia, PA 19111 U.S.A.
Phone: 215-728-3829
FAX: 215-728-3616
E-mail: mk_shin@fccc.edu

Shioda, Toshihiro M.D., Ph.D.
MGH Cancer Center
Department of Tumor Biology
13th Street, Building 149, 7th Floor
Charlestown, MA 02129 U.S.A.
Phone: (617) 726-5625
FAX: (617) 726-5637
E-mail: shioda@helix.mgh.harvard.edu

Shore, Leonard J. Ph.D.
Unilever Research
Bioscience Department
45 River Road
Edgewater, NJ 07020 U.S.A.
Phone: 201-840-2956
FAX: 201-840-8291
E-mail: leonard.j.shore@unilever.com

Silvers, Willys K. Ph.D.
No Current Address

Slominski, Andrzej T. M.D., Ph.D.
University of Tennessee
Department of Pathology
930 Madison Avenue, Suite 599
Memphis, TN 38163 U.S.A.
Phone: 901-448-3741
FAX: 901-448-6979
E-mail: aslominski@utmem.edu

Solis-Herrera, Arturo M.D. *
Lopez Velarde 108, centro
Aguascalientes, Ags, CP 20000 MEXICO
Phone: 052-449-9157934
FAX: 052-449-9162901
E-mail: svadamda@ags.ciateq.mx

Spaulding, Deborah T.
University of Oklahoma Health Sciences Center
Department of Biochemistry and Molecular Biology
655 N. Research Parkway, Room 542
Oklahoma City, OK 73104 U.S.A.
Phone: 405-271-7166 (ext 6)
FAX: 405-271-7152
E-mail: deborah-spaulding@ouhsc.edu

Spritz, Richard A. M.D.
University of Colorado Health Sciences Center
Human Medical Genetics Program
4200 E. Ninth Avenue, B161
Denver, CO 80262 U.S.A.
Phone: 303-315-0409
FAX: 303-315-0407
E-mail: richard.spritz@uchsc.edu

Strickland, Faith M. Ph.D.
Henry Ford Hospital
Department of Dermatology, 4D49
One Ford Place
Detroit, MI 48202 U.S.A.
Phone: 313-874-3385
FAX: 313-874-3770
E-mail: fstrick1@hfh.org

Sugumaran, Manickam Ph.D.
University of Massachusetts at Boston
Department of Biology
100 Marrissey Boulevard
Boston, MA 02125 U.S.A.
Phone: (617) 287-6600
FAX: (617) 287-6650
E-mail: manickam.sugumaran@umb.edu

Swank, Richard T. Ph.D.
Roswell Park Cancer Institute
Department of Molecular and Cell Biology
Elm & Carlton Streets
Buffalo, NY 14263 U.S.A.
Phone: (716) 845-3429
FAX: (716) 845-5908
E-mail: richard.swank@roswellpark.org

Szabo, George Ph.D.
No current address

Tada, Akihiro Ph.D.
POLA Research & Development Laboratories
560 Kashio-cho, Totsuka-ku
Yokohama, 244-0812 Japan
Phone: 81-45-826-7232
FAX: 81-45-826-7239
E-mail: akihiro@pola.co.jp

Taylor, Susan C. M.D.
St. Luke's Roosevelt Hospital Center
Director, Skin of Color Center
New York, NY 10025 U.S.A.
Phone: 212-523-3888
FAX: 212-523-3808
E-mail: drstaylor1@aol.com

Thibaudeau, Giselle Ph.D.
Mississippi State University
Department of Biological Sciences
Harned Hall
Mississippi State, MS 39762 U.S.A.
Phone: (662) 325-7572
FAX: (662) 325-7939
E-mail: giselle@biology.msstate.edu

Tomecki, Kenneth J. M.D.
Cleveland Clinic A61
9500 Euclid Avenue
Cleveland, OH 44195 U.S.A.
Phone: (216) 444-2651
FAX: (216) 445-6365
E-mail: tomeckk@ccf.org

Weiner, Lorin Ph.D.
Massachusetts General Hospital, Harvard Medical School
Cutaneous Biology Research Center, Department of
Dermatology
MGH-East, 3rd Floor, Building 149
13th Street
Charlestown, MA 02129 U.S.A.
Phone: 617-724-8274
FAX: 617-726-4453
E-mail: lorin.weiner@cbr2.mgh.harvard.edu

Wijsekera, Dilshika H. M.Sc.
University of Arkansas
Department of Poultry Science
1260 W. Maple Street, O-114
Fayetteville, AR 72701 U.S.A.
Phone: 479-575-2098
FAX: 479-575-7139
E-mail: hwijese@uark.edu

Yang, Sun Ph.D.
UCI Medical Center
Chao Family Comprehensive Cancer Center
101 The City Drive South
Building 23, Room 436
Orange, CA 92868 U.S.A.
Phone: 714-456-3438
FAX: 714-456-2240
E-mail: syang2@uci.edu

Yoon, Hyung Sik
14-307 Rex Apartment, 300-3, Dongbuichon-Dong
Yongsan-Gu
Seoul, 140722 SOUTH KOREA
E-mail: epu2@unitel.co.kr

Yoshida, Masaki
Kanebo, Ltd.
Basic Research Laboratory
5-3-28, Kotobuki-cho, Odawara-shi
Kanagawa-ken, 250-0002 JAPAN
Phone: 81-495-34-6116
FAX: 81-495-34-3037
E-mail: myos@oda.cos.kanebo.co.jp

Yu, Mingke Ph.D. *
University of Southern California
Department of Pathology
2011 Zonal Avenue, HMR 313
Los Angeles, CA 90033 U.S.A.
Phone: 323-442-1982
FAX: 323-442-3049
E-mail: mingkeyu@usc.edu